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Abstract 
 
            The high affinity, selective dopamine transporter ligand GBR 12909 has served as a 
template for the design of two novel classes of dopamine transporter ligands.  A series of 3-[2-
(diarylmethoxyethyidenyl)]-N-substituted tropane derivatives were synthesized and the binding 
affinities of these compounds were determined at the dopamine (DAT), serotonin (SERT) and 
norepinephrine (NET) transporters in rat brain tissue preparations.  The tropane derivatives were 
found to exhibit more potent affinity and selectivity for DAT than GBR 12909.  From the SAR 
of the tropane analogues and GBR 12909, a novel series of 3-[2-(diarylmethoxyethylidenyl)]-N-
substituted azetidine derivatives has been developed.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Dopamine, serotonin, norepinephrine, tropane, GBR 12909, azetidine
  
 
1 
Introduction 
Cocaine 
Cocaine (1) is a powerful stimulant that is isolated from the leaves of Erythroxylum coca, 
a plant found in South America.1 The psychostimulant affects the central nervous system causing 
euphoria, an increase in heart rate and an increase in locomotor activity.2 Cocaine is known to be 
highly addictive and a life-threatening problem.  
Although cocaine inhibits the serotonin, norepinephrine, and dopamine reuptake systems, 
it is believed that cocaine binding to the dopamine transporter is responsible for the stimulant 
and reinforcing effects of the drug.3 Cocaine is believed to block the reuptake of dopamine (2) at 
the dopamine transporter. This leads to an increased concentration of dopamine in the synapse 
and increased occupation of postsynaptic receptors by dopamine that causes the increased 
stimulation and up-regulation of dopamine receptors.3, 4 
N
CH3
CO2CH3
O
O
NH2
HO
OH
Dopamine (2)(-) Cocaine (1)  
Cocaine is a psycho stimulant that has historical significance.  Its history includes 
enhancing the lifestyle of the ancient Incan empire, an anesthetic for optical surgery, prescribed 
by Sigmund Freud for depressed patients and finally as the worlds most addictive and exploited 
drug.  Ancient Incans would chew the leaf of the coca plant, Erythroxylum coca, along with an 
alkaline mixture to extract the cocaine from the leaf when traveling on foot and were able to 
travel greater distances in less time and with less food.  It was known that the effects of the coca 
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leaf without the alkali mixture were not produced.  Cocaine in the free-base form is known today 
as the popular drug, “crack”, or crack-cocaine.5 
            Sigmund Freud prescribed cocaine to his more depressed patients and eventually Freud 
became addicted to cocaine as well.6, 7 Cocaine was demonized as being used by the poor, 
uneducated members of society, however, at the beginning of the 1900’s, cocaine was more 
popular with the aristocrats and well-to-do people of society because of the high cost of cocaine.  
Many became addicted to the drug.  Cocaine is the most addictive drug in the world and has been 
suggested to be more addictive in adolescence than in adults. 6, 7   Studies have shown that the 
addictive properties of cocaine are more pronounced in periadolescent rats than in adult rats. 7   
            In South America, countries like Peru and Columbia were the major suppliers of cocaine 
to the United States and other parts of the world.  Cocaine production was, and still is, a way of 
life and the sole means of income for many farmers to support their families.  Because of the 
climate in these countries and the long life of the cocaine-producing plant, cocaine farming is 
more economical than some food production.6 
In the late 1970’s and early 1980’s, cocaine had grown into a billion dollar industry and 
Reagan’s War on Drugs campaign only added fuel to the fire.  Drug lords in Columbia, like 
Pablo Escobar, started sending as many as 80 airplanes full of cocaine to the United States 
everyday with the idea that the Drug Enforcement Agency (DEA) could only catch a few planes 
on any given day.  Pablo Escobar was the most notorious drug lord in South America making 
over a million dollars a day.  In the 1980’s it was estimated that children as young as 12 years old 
used cocaine.  In 2001, approximately 15.9 million Americans aged 12 years or older used illicit 
drugs; 1.2 million are current cocaine users.8 The National Drug Control Policy office estimates 
that number to be higher than 3.5 million chronic cocaine users.9 
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Cocaine Mode of Action 
Cocaine binds to the monoamine transporters dopamine (DAT), serotonin (SERT) and 
norepinephrine (NET) blocking the reuptake of these neurotransmitters through the monoamine 
transporters.10 Cocaine also binds to adrenergic, muscarinic, -receptors and sodium channels. 
Specifically, dopamine is normally released into the synapse and reuptake occurs across the 
dopamine transporter located on presynaptic nerve terminals.8 Two Na+ ions and one Cl- ion bind 
at the transporter to allow for dopamine reuptake and finally the Na+ and Cl- ions cross the 
dopamine transporter as well.   The mode of action of cocaine and subsequent addictive 
properties are caused by cocaine binding to the dopamine transporter and blocking the reuptake 
of dopamine in the synapse.  Structure-activity relationship (SAR) studies have suggested that 
structurally diverse dopamine uptake inhibitors have binding affinities associated to two different 
binding sites on the dopamine transporter. 11-14 It was also mentioned by Izenwasser that cocaine 
competitively binds to a Na+ ion binding site on the dopamine transporter suggesting cocaine 
binding at two binding sites in the nucleus accumbens.15   
            To be a potential cocaine therapeutic, a high binding affinity for the dopamine 
transporter, a long duration of action and slow onset of the drug would be desirable.8 A slow 
onset of the drug should not cause the same effects as cocaine which has a fast onset; therefore, 
the “rush” is not induced by increasing the amount of dopamine in the synapse by the drug.  A 
long duration of the drug would allow the drug to stay bound to the dopamine transporter and 
eventually be washed away. 
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Binding Constants 
 The concentration of drug needed to bind to the dopamine transporter can be measured 
by determining the concentration needed to produce 50% inhibition, (IC50), of a radiolabeled 
ligand selective for dopamine transporter binding.  When the drug displaces 50% of the 
radiolabeled ligand from the dopamine transporter, the concentration is determined as the IC50 
value.  The binding affinity is expressed as the inhibition constant Ki, which is calculated from 
the measured IC50 value by using the equation manifested by Cheng and Prusoff.
16
  The substrate 
concentration, S, is the radio labeled ligand and KM is the Michaelis constant for the substrate 
and is determined specifically for each substrate.  Since these are inhibition constants, smaller Ki 
values correspond to increased potency (affinity) at the transporter. 
Ki = IC50/(1 + S/KM) 
            Selectivity for the dopamine, serotonin and norepinephrine transporters is determined by 
the ability of the drug to displace the radio labeled ligands [3H]WIN 35,428, [3H]citalopram, and 
[3H]nisoxetine, respectively, from the monoamine transporters.7, 8 
GBR 12909 Structure Activity Relationship 
The piperazine compound, GBR 12909 (3) synthesized by van der Zee et al., was found 
to be a high affinity ligand (Ki = 12 nM) for the dopamine transporter.
17 GBR12909 is selective 
for the dopamine transporter over the serotonin transporter and is not self-administered in non-
human primates; 18, 19 however, GBR 12909 also binds to -receptors, which is believed to be the 
source of dysphoria observed in humans.20 
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N N
O
F
F
GBR12909 (3)
 
Based on the selectivity of GBR 12909 for the dopamine transporter over the serotonin 
transporter (SERT/ DAT = 35), GBR 12909 has been identified as a lead compound for the 
development of more selective analogues.  Substitution around the rings of the benzhydryl 
moiety plays a vital role in dopamine transporter binding. Varying the size and shape of the ring 
and number of nitrogen atoms in the ring causes a variation in binding affinity.  Furthermore, 
alkyl substitution on the nitrogen atom distal to the benzhydryl group has an effect on dopamine 
transporter binding.  The distal and proximal positions are: 
N NO
F
F
proximal
distal
 
            The benzhydryl moiety plays a vital role in dopamine transporter binding.  Mono-
substitution at the para-position of the phenyl rings with a halide increases affinity binding.  
High-affinity binding is displayed with dihalogen-substitution at the para-position with F > Cl > 
Br. Kulkarni et al. suggested that when there is a substituent, especially at the ortho-postion on 
the ring, this may interfere with the orientation of the phenyl rings by changing the torsion angle 
of the diphenylmethoxy moiety which causes a decrease in dopamine transporter binding 
affinity.21 Small halogens at the para- and meta-positions of the diphenylmethoxy moiety can be 
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tolerated at the dopamine transporter, but high binding affinity requires 4,4’-difluoro phenyl 
substitution.21 Many structure activity relationship studies have shown that while the difluoro 
benzhydryl moiety causes an increase in binding affinity at the dopamine transporter, it is the 
desfluoro benzhydryl moiety that exhibits the greatest selectivity for the dopamine transporter 
over the serotonin transporter. 
            Many structure-activity relationship studies have shown different binding affinities by 
varying the shape and size of the piperizine ring or by incorporating different functional groups 
into the piperazine skeleton of GBR 12909.22-24 The piperazine analogue 4 showed dopamine 
transporter binding affinity equal to that of GBR 12909.25 Winfield et al.24 incorporated an imide 
functionality into the piperazine ring to give 5 which led to a decrease in binding affinity at the 
dopamine transporter.  The expansion of the piperazine ring showed a limit to the size to which it 
can be expanded before the binding affinity starts to decrease.  Eight-membered perhydro-
diazocine rings 6 showed decreased selectivity and binding affinity for the dopamine transporter 
and were the limit to size the ring could be expanded.  When the rings were opened (7), binding 
affinities increased but were not as potent and selective as GBR 12909.26 
N N
O
F
F             
N N
O
F
F
O
O
 
4 5 
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N NO
F
F
O
N
N
 
                                     6                                                                 7 
            The N-alkyl chain length and substituent seem to enhance the potency and selectivity for 
the dopamine transporter if a phenylpropyl moiety is incorporated into the piperazine 
analogues.27-30 Changing the substituents at the nitrogen atom of the piperazine analogues greatly 
affected dopamine transporter binding.  It has also been demonstrated that a hydroxyl moiety 
incorporated onto the phenylpropyl moiety at the benzylic position of the GBR 12909 analogue 8 
possessed binding affinity for the dopamine transporter.31 The (S)-2-hydroxylated analogue 9 of 
GBR 12909 exhibited high binding affinity (DAT Ki = 0.75 nM) and was more selective than 
GBR 12909 or the (R)-2-hydroxylated for the dopamine transporter.  The (S)-9 analogue also 
increased extracellular dopamine levels in rats similar to GBR 12909 and was more potent than 
(R)-9. 
N N
O
F
F
OH
 
N N
O
F
F
OH
 
                 8                                                                    9 
It has been proposed that high affinity dopamine transporter ligands reduce             
cocaine-maintained responding in rhesus monkeys.31 During these behavioral studies, the rhesus 
monkey pushes a lever that administers a dose of cocaine, causing a positive correlation in 
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response to pushing the lever.  When the rhesus monkey pushes the lever and the drug that 
produces no positive effects, the monkey stops pushing the lever because there is no reward 
associated with it.  The (S)-9 analogue was found to substitute for cocaine and was more potent 
than GBR 12909 and the R isomer.  In this series of analogues, the (S)-2-hydroxyl unit was 
found to be vital for dopamine transporter binding in vitro and in vivo cocaine maintained 
responding. 
            The bis-4-fluorophenyl substituted GBR 12909 compounds usually have higher binding 
affinities, but are less selective for the dopamine transporter than the unsubstituted diphenyl 
analogues.  Following this trend, the unsubstituted diphenyl 2-hydroxylated analogues of 9 
showed high affinity for the dopamine transporter, although not as high as the fluorine 
substituted analogues, and the selectivity for the dopamine transporter over the serotonin 
transporter was in fact higher than the fluorine substituted analogues.  Interestingly, the 
unsubstituted (S)-2-hydroxylated analogue was 900-fold more selective for the dopamine 
transporter over the serotonin transporter.31 
            The phenylethyl 2-hydroxylated analogue 10 followed the trend that a phenylpropyl 
moiety is needed for more potent and selective dopamine transporter ligands.  Following the 
trend of the analogues of 9, the S isomer was more selective and more potent for the dopamine 
transporter than the R isomer.  To increase the selectivity for the dopamine transporter, structure-
activity relationship studies have shown that unsubstituted diphenyl rings and a phenylpropyl 
chain are needed.  The R isomer of 10 incorporates the structure needed for the opposite effect 
for selective dopamine transporter binding and is one of the least selective dopamine transporter 
ligands (SERT/ DAT = 0.5).  This suggests that the 2R-hydroxyl group is another factor causing 
the decrease in dopamine transporter selectivity over serotonin transporter selectivity.31 
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N N
O
F
F
OH
 
                                  10 
A series of analogues 11 were synthesized32 that incorporate heteroaryl groups, chain 
elongation at N1, derivatization of the heteroatom with chain elongation and substitution of the 
aryl ring.  When R3 and R2 are hydrogen atoms and an unsubstituted aniline moiety is used, the 
binding affinity for the dopamine transporter was equipotent to that of GBR 12909.  When the 
aniline analogue was changed to a benzyl amine, the binding affinity was equipotent with GBR 
12909 but decreased as the number of methylene units was increased.   
N N1
O
N
F
F
OR3
(CH2)n
R2
X
R1
 
                                    11 
            Para substitution (R1) with -F, -OMe, -Me and -Cl showed no significant difference in 
binding affinity at the dopamine transporter.  However, a bulkier and strongly electron-
withdrawing 4-NO2 moiety showed a slight decrease in binding affinity.  When the bulkier 
substituents were incorporated onto the ring, binding affinities were significantly decreased.  The 
4-N(CH3)2 analogue had an IC50 = 109 that is much lower than GBR 12909 (IC50 = 12 nM) and 
may be caused by steric bulk and basicity of the nitrogen.  The 4-pyridinyl analogue showed a 
decrease in binding affinity (IC50 = 32 nM) for the dopamine transporter which indicates that the 
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basicity of the pyridinyl nitrogen may cause some unfavorable interaction with the binding site 
of the dopamine transporter.32  
            Substitution of the 3-amino-2-propanol nitrogen with a methyl moiety showed no 
decrease in binding affinity.  However, substitution with more electron-withdrawing acetyl and 
mesyl moieties elicited less potent binding affinities at the dopamine transporter.  When the 
hydroxyl group was modified by replacing it with an acetoxy or methoxy moiety, the binding 
affinity decreased which suggests that the hydroxyl moiety is important in these compounds for 
hydrogen-bonding or hydrophilic interactions at the dopamine transporter.32 
As previously mentioned, GBR 12909 possesses two nitrogen atoms in its structure 
although two nitrogen atoms are not necessary for binding to the dopamine transporter.  Dutta et 
al.33 proved which of the two nitrogen atoms was essential for dopamine transporter binding 
affinity and selectivity.  By replacing the nitrogen atom proximal to the benzhydryl moiety with 
a carbon atom in the piperazine analogue, binding affinity for the dopamine transporter increased 
more so than by replacing the nitrogen atom distal from the benzhydryl group.   
N NO
F
F
proximal
distal
 
            The cinnamyl derivative 12 of GBR 12909 demonstrated comparable potency (DAT IC50 
= 1.9 nM) as a more rigid analogue of GBR 12909.34 Interestingly, the piperidine analogue 13 
showed higher affinity for the dopamine transporter than the piperazine analogue 12 and was 
more potent for the dopamine transporter over the serotonin transporter, (SERT/DAT = 104). 28 
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N N
O
F
F
NO
F
F  
12                                                               13 
When the piperidine analogue 13 was incorporated with an alkyne moiety in place of the 
trans double bond, the affinity for the dopamine transporter decreased suggesting that a linear 
conformation was not favorable at the transporter.  Further, the naphthylmethyl piperidine 
derivative 14 showed high affinity for the dopamine transporter (DAT Ki = 0.71 nM) and an 
increase in dopamine transporter selectivity over the serotonin transporter (SERT/ DAT = 323).28 
This suggests that the piperazine and piperidine analogues are not binding to the dopamine 
transporter in the same manner.   
N
O
F
F  
                               14 
            The piperidine analogues of GBR 12909 have been reported to show a preference for a 
one-carbon chain length between the nitrogen and the aryl derivative that is usually a benzyl 
moiety.28-33 The iodo analogue 15 showed increased binding affinity for the dopamine transporter 
(DAT IC50 = 0.96 nM) and increased selectivity over the serotonin transporter (SERT/ DAT = 
3041). 29 Interestingly, when the large iodine atom is in place of the naphthyl group, the binding 
affinity and selectivity for the dopamine transporter increases.  This suggests that in these 
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piperidine compounds, a large halide atom at the para-position eliminates the need for such 
planar -systems like the naphthyl-substituted analogues.  It was also suggested that the large 
iodine atom might induce changes in the lipophilic and steric interactions at the dopamine 
transporter.29 
NO
I
 
                            15 
            Introduction of a para-ethenyl benzyl 16 moiety or a para-ethynyl benzyl 17 moiety was 
tolerated by the dopamine transporter and showed selectivity for the transporter over the 
serotonin transporter but were not as potent or selective as the iodo analogue 15.  However, the 
para-ethenylbenzyl analogue 16 showed greater potency for dopamine uptake inhibition than 15.  
It was also noted that in the 4-acetylenic substituted benzyl analogues, if the terminal H-atom 
was replaced with a methyl group to give 18, the binding affinity decreased due to increased 
steric bulk.29   
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N
O
N
O
N
O
H  
              16                                 17                                       18 
Substitution around the benzyl ring of the piperidine analogues exhibited a significant 
difference in binding affinity.  Typically, para-substitution led to higher affinities at the 
dopamine transporter whereas meta- or ortho- substitution decreased in binding affinity at the 
dopamine transporter.  Electron-withdrawing groups on the N-benzyl ring were also favored for 
dopamine binding affinity over electron-donating groups.  The desfluoro-piperidine analogues 
usually are not as potent as the fluorine substituted benzhydryl analogues, but do demonstrate 
better selectivity for the dopamine transporter over the serotonin transporter.  It is noteworthy 
that the 4-NO2 deslfuoro analogue 19 was highly selective for the dopamine transporter over the 
serotonin transporter (SERT/ DAT = 859) and in dopamine uptake inhibition studies (SERT/ 
DAT = 1310). 30 
NO
NO2
 
                               19 
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            Many of the piperazine and piperidine analogues demonstrated high binding affinity and 
selectivity for the dopamine transporter by incorporating many different functional groups 
around the molecule.  Hydroxy groups incorporated into the alkyl chains or substitution around 
the benzyl moiety has been shown to be important for high affinity binding.  Introduction of a 
hydroxy group into the piperidine ring served to present compounds that were potent at the 
dopamine transporter.34 The racemic cis and trans piperidine analogues 20 proved to be potent 
dopamine transporter ligands. However, the resolved trans (+)-R, R analogue (DAT IC50 = 0.46 
nM) had a high binding affinity much greater than GBR 12909 and its unhydroxylated parent 
piperidine compound and was highly selective for the dopamine transporter over the serotonin 
transporter (SERT/ DAT = 7800).  The cis analogue was approximately three times less potent 
than the racemic trans diastereomer.  This illustrates the stereochemical importance of the 
hydroxyl moiety in these compounds for binding at the dopamine transporter.  Interestingly, the 
(+)-R, R analogue had a lower dopamine uptake inhibition than what is normally expected for 
such a potent ligand. 25, 34 
N
O
F
N
O
F
OHHO
(+)-R,R-trans-20 cis-20  
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            In vivo studies for the racemic and resolved trans diastereomer produced substantial 
results when compared with cocaine.  Cocaine produced maximum locomotor responses at 10 
mg/kg within the first ten minutes and tapered off to that of the vehicle within three hours after 
the initial injection.  It took 56 mg/kg of the racemic mixture to invoke maximum response 
between twenty to thirty minutes and continued to invoke a locomotor response for three hours.  
The (+)-trans isomer induced a response at 56 mg/kg at twenty minutes but locomotor activity 
decreased to that of the vehicle.  Interestingly, the locomotor activity for a 30 mg/kg dose of 
trans-(+)-20 remained elevated throughout the three-hour duration.  Significantly, the (-)-trans 
isomer only showed locomotor response at doses of 100 mg/kg within twenty minutes but 
decreased almost immediately to that of the vehicle and remained constant throughout the rest of 
the three hours.  In a cocaine discrimination response test in rats trained to discriminate cocaine, 
all three compounds tested produced a response in rats.  This indicates that the compounds are 
not having a problem crossing the blood-brain barrier to reach the dopamine transporter in the 
central nervous system.25, 34 
             As has been previously reported, replacing the nitrogen atom distal to the benzhydryl moiety 
decreases binding affinity at the dopamine transporter.29 A series of tropane-based analogues 
have been synthesized that show the same trend in binding as the piperidine analogues 
synthesized by Dutta.  The fluorine-substituted analogue 21 (X = F) (DAT Ki = 144 nM) was 
shown to be more potent than cocaine but was significantly less potent than GBR 12909.35 The 
chlorine, methyl and methoxy substituted analogues were shown to have binding affinities 
equipotent or less than that of the fluorine substituted analogue.  Usually, the fluorine-substituted 
analogues of any series of dopamine transporter ligands follow a trend that binding affinities 
increase with fluorine-substitution.  However, the unsubstituted analogue (X = H) was shown to 
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have the highest binding affinity at the dopamine transporter over the substituted analogues in 
the series (DAT Ki = 98 nM).
35  Interestingly, Bradley et al. reported the binding affinity for 21 to 
be equipotent with that observed with the unsubstituted analogue 22a (DAT Ki = 99 nM).
36 The 
rigidity of the tropane ring system in 21 may cause a conformation suitable for binding at the 
dopamine transporter where the difference in which nitrogen is replaced is not a factor for high 
binding affinities in the tropane-class of compounds.  Therefore, it was shown that a piperazine 
ring system was not needed for potent binding at the dopamine transporter and nitrogen 
replacement was no longer a factor.   
The benzyl analogues 22 demonstrated decreased potency at the dopamine transporter.  
Interestingly, the 4, 4’-difluoro analogue of 22b was shown to be the most potent (DAT Ki = 5.7 
nM) and most selective dopamine transporter ligand (SERT/ DAT = 251) in the series.  The 4, 
4’-dichloro analogue 22c was the least selective (SERT/ DAT = 9).  These findings run counter 
to what is normally expected for GBR-based dopamine transporter ligands and is linked to the 
incorporation of the benzyl group.36 
N
H
O
X
X
      
N
O
X
X
H
 
21                                                           22a     X = H 
                                                                   b     X = F 
                                                                   c     X = Cl  
 
 
  
 
17 
The N-methyl 3-derivatives 23 were compared to the benzyl and phenylpropyl 
derivatives and were generally less potent than the phenylpropyl analogues 22 and slightly more 
potent than the benzyl analogues 21.  The desfluoro analogue of 23a was the most selective 
(SERT/DAT = 243) analogue for the dopamine transporter over the serotonin transporter than its 
difluoro, dichloro or monochloro substituted analogues but the least potent (DAT Ki = 58 nM) of 
the series.  Usually, the desfluoro analogues show greater selectivity for the dopamine 
transporter but tend to have diminished potency at the transporter.36 
N
O
X
X
H
               
N
O
X
X
H
 
                      23a     X = H      X = H, Cl                         24 
                          b     X = F 
                          c     X = Cl 
The phenylpropyl analogues 24 demonstrated high binding affinities for the dopamine 
transporter except for the dichloro analogue, which was the least selective of the series (SERT/ 
DAT = 4).  The difluoro analogue was shown to be the most potent in the series (DAT Ki = 7.4 
nM) but was not very selective for the dopamine transporter (SERT/ DAT = 24).   The difluoro 
analogue showed a comparable affinity to that of ethylidene analogues 25 although it was not as 
selective for the dopamine transporter.36 
The ethylidene analogues 25 were synthesized as racemic compounds and designed to 
elucidate the stereochemical limits of the dopamine transporter.  Constructing a more rigid 
compound proved to enhance the potency and selectivity at the dopamine transporter.  The least 
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potent (DAT Ki = 48 nM) and least selective (SERT/ DAT = 113) of the series was the N-benzyl 
desfluoro benzhydryl analogue.  Contrary to previous results, the difluoro substituted N-benzyl 
analogue was significantly more potent (DAT Ki = 7.9 nM) but was highly selective for the 
dopamine transporter (SERT/ DAT = 281).  The N-phenylpropyl desfluoro analogue was more 
potent than its N-benzyl congener and was the most selective of the ethylidene analogues (SERT/ 
DAT = 327). Although less selective for the dopamine transporter than the desfluoro analogue, 
the N-phenylpropyl difluoro substituted analogue was slightly more potent (DAT Ki = 3.7 nM) 
than the other analogues in the series.  The results proved that sp2-hybridization of the C3-carbon 
atom increased binding affinity and selectivity for the dopamine transporter.36 
During a recent biological study by the NIDA Medication Development Program37, the 
-tropane isomers were shown to be more potent than GBR 12909 at the dopamine transporter in 
HEK cells expressing cDNA for the human dopamine transporter (HEK-hDAT).  Specifically, 
the tropane analogue, 8-benzyl-3-bis(4-fluorophenyl) methoxyethyl-8-aza-bicyclo-
[3.2.1]octane, [ALB-III-141 (22b), Ki = 147 nM]
37 exhibited dopamine transporter (HEK-hDAT) 
affinity approximately twice that of cocaine.  In addition, tropane derivative 25 proved to be 
even more potent than the -tropane isomers, [ALB-IV-41 (25), Ki = 39 nM]. The alkylidene 
derivative 25 was found to be equipotent with GBR 12909.37 
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            The compounds 22 and 25 differ from GBR 12909 by incorporation of the more rigid 
tropane skeleton and one nitrogen atom in the bicyclic system.  The similarities of the tropane 
analogues to that of GBR 12909 include the N-alkyl chain, the benzhydryl moiety and the tether 
between the benzhydryloxy moiety and the parent skeleton.  These compounds lack two 
nitrogens unlike that of GBR 12909 concluding that the second nitrogen is not necessary for 
potent dopamine transporter binding affinity. 
            Zhang et al.38 synthesized a series of N-methyl alkylidenyl tropane analogues 26 and 27.  
These compounds demonstrated comparable results to previous trends of other dopamine 
transporter ligands.  The 4, 4’-difluoro substituted analogues showed increased binding affinity 
for the dopamine transporter and increased dopamine uptake inhibition over the desflouro 
analogues.  This is consistent with previously reported GBR 12909 analogues.  Usually, the 
desfluoro analogues show increased selectivity for the dopamine transporter when compared to 
the difluoro substituted analogues. 
The 4, 4’-difluoro substituted analogue of 26 exhibited high binding affinity for the 
dopamine transporter (DAT Ki = 19 nM) and increased selectivity for the dopamine transporter 
over the serotonin transporter (SERT/ DAT = 189).  The amide analogues 27 showed decreased 
binding affinity for the dopamine and serotonin transporters, decreased selectivity for the 
dopamine transporter and decreased dopamine uptake inhibition.38 
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Rationale for Design of Novel GBR-Related Analogues 
            GBR 12909 exhibits potency at the dopamine transporter but the piperazine ring allows 
for this compound to bind to -receptors in the brain.  It is believed that by binding to these 
receptors GBR 12909 caused patients to experience dysphoria during human clinical trials and, 
therefore, GBR 12909 was abandoned as a potential medication.  The tropane ring offers a more 
rigid bicyclic skeleton that decreases the flexibility of the molecule and subsequently could lead 
to a potential decrease in binding to -receptors in the brain.  The structure-activity relationship 
studies of Dutta et al. proved that the distal nitrogen atom is the one needed for high affinity 
binding to the dopamine transporter.29 Studies have suggested that increased pharmacokinetics 
may be due to increased lipophilicity of the analogues.39-41 
           GBR 12909 has a clogP value of 5.37.  If a drug is too lipophilic, it will have difficulty 
crossing the blood-brain barrier and get stuck in the lipid bilayer.48 Obviously with a clogP value 
of 5.37, GBR 12909 is very lipophilic and would not cross the blood-brain barrier very rapidly.  
Cocaine has a clogP value of 3.24 and is able to cross the blood-brain barrier very rapidly and 
occupy the dopamine transporter.  Crack, the freebase form of cocaine has a very fast onset of 
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action and is subject to abuse because it is usually inhaled into the lungs where it can enter the 
blood stream rapidly where it is carried to the brain. 
Objectives 
            As mentioned before, GBR 12909 has a high binding affinity and is selective for the 
dopamine transporter over the serotonin and norepinephrine transporters and is not self-
administered in non-human primates.18, 19 However, GBR 12909 does bind to -receptors, which 
is believed to be the cause of dysphoria in humans.17-20 The goal of this research was to develop 
novel GBR 12909 tropane hybrid and azetidine analogues for potent dopamine transporter 
ligands as potential therapeutics for cocaine addiction.  While utilizing the tropane skeleton, 
diminished -receptor activity and increased binding affinity and selectivity at the dopamine 
transporter is anticipated.  The objective for the design of the azetidine analogues was to design 
compounds that were less lipophilic than the GBR 12909 tropane hybrid analogues.  The 
azetidine compounds would keep the rigidity needed for binding to the dopamine transporter and 
would have lipophilicity less than or equal to GBR 12909. 
Cocaine binds to the dopamine transporter stereoselectively.38 In addition, Meltzer et al. 
found that methylphenidate binds to the dopamine transporter stereospecifically but did not 
exhibit addictive properties like that of cocaine.43 It is interesting to note that the 3-analogues of 
the tropane-based series of compounds have typically been less potent than their 3-conformers. 
This indicates that, like cocaine, there is a stereoselective preference in binding affinity to the 
dopamine transporter as well as the other monoamine transporters.  In other studies to synthesize 
potent dopamine uptake inhibitors, a 3-diphenylmethoxyalkyl moiety of the tropane-based 
analogues have displayed low binding affinity for the dopamine transporter.  Changing the 
stereochemistry and substituents around the tropane ring greatly affects the binding affinity.                         
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            Therefore, it was of interest to synthesize compounds that had a stereochemical 
preference for the dopamine transporter.  It was envisioned that resolution of the racemic mixture 
of the alkyidenyl tropane compounds would enhance the binding affinity and selectivity at the 
dopamine transporter.  Modifying the N-substitution could also enhance selectivity and potency. 
Benztropine and phenyltropane analogues substituted at the 2-position have shown to have high 
binding affinity to the dopamine transporter. Benztropine analogues incorporate a diphenly-
methoxy moiety that is significantly bulkier and less water soluble than the phenyl moiety of the 
3-phenyltropane analogues. Increasing the carbon chain length and steric bulk of the substituent 
on the nitrogen led to increased binding affinity to the dopamine transporter as well as increasing 
the lipophilicity of the compound.43-49 To this end, a series of GBR-tropane hybrid analogues 
(Figure 1) and GBR-related azetidine analogues (Figure 2) were designed to further investigate 
the binding motifs of monoamine transporters in the hope of identifying new lead compounds for 
development of a cocaine medication. 
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Figure 1.  Target GBR 12909 Tropane Hybrid Analogues 
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Figure 2.  Target Azetidine Analogues 
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Synthesis of 8-alkyl-3-diarylmethoxyethylidenyl-8-azabicyclo[3.2.1]octane analogues 
            It was envisaged that the synthesis of these analogues would commence with the 
commercially available 3-tropinone (35).  In the retrosynthetic analysis (Scheme 1), the 
olefination of the protected 3-tropinone would provide a scaffold (34) for incorporating 
stereochemistry into the molecule.  Subsequent reduction of the conjugated ester 34 from the 
olefination would provide the allylic alcohol 33 and further ether synthesis would furnish the 
substituted diphenylmethoxyethylidene analogues.  Deprotection of the secondary nitrogen atom 
would set the stage for the final derivatization to provide the final alkylidene analogues (28).   
            The 3- tropane analogues 22 and 24 synthesized by Bradley et al.37 were shown to be 
fairly potent dopamine transporter selective ligands.  However, it was thought that bringing the 
stereochemistry at the 3-position into a more rigid planar conformation by incorporation of a 
double bond would lead to analogues that were more potent and more selective for the dopamine 
transporter.  As illustrated in Scheme 2, it was concluded that the alkylidene could be resolved 
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into the enantiomeric forms of the molecule.  Resolution could be carried out by various 
techniques that would set the stage early for further derivatization of the analogues and 
preparation of enantiomerically pure ligands.   
 
Scheme 1.  Retrosynthesis of Tropane Analogues 
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Scheme 2.  Retrosynthesis of Resolved Enantiomers 
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Synthesis of 3-diphenylmethoxyalkyl-8-substituted-azetidine analogues 
            As mentioned previously, the rationale for synthesizing the novel azetidine analogues 
was to keep the rigidity of the tropane hybrid analogues but decrease the lipophilicity for better 
bioavailability.  Compared to the tropane hybrid analogue (28Ha) (clogP = 6.29) the azetidine 
analogue (29) is significantly less lipophilic (clogP = 5.14) and would be expected to have better 
bioavailability.  These four-membered nitrogen rings are highly strained molecules and the 
stability of these molecules during the synthesis was of great importance.  Further, when 
subsequent incorporation of a double bond is introduced, the molecule adopts an almost planar 
conformation, Figure 3.  These semi-planar azetidine analogues could be developed from a novel 
synthetic strategy that keeps these highly strained compounds intact throughout the process. 
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Figure 3. Conformation of 3-Alkylidenylazetidine 29 and 3-Alkylazetidine 30. 
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            The synthetic approach for these novel azetidines can be seen in the retrosynthetic 
analysis depicted in Scheme 3.  The synthesis would commence from the straightforward 
reaction of the commercially available starting materials epichlorohydrin and the appropriate 
alkylamine (i.e. benzylamine).  Further oxidation of the alcohol formed from the ring-closed 
product would provide the key 3-azetidinone 37.  This would be subjected to Horner-
Wadsworth-Emmons olefination and subsequent reduction to furnish the allylic alcohol 36.  To 
finish the synthesis and obtain the final product, a straightforward ether synthesis with the 
appropriately substituted benzhydryl derivative would provide the target diphenylmethoxy-
alkylidenyl-N-substituted-azetidine analogues 29.  
 
Scheme 3.  Restrosynthesis of Unsaturated Azetidine Analogues 
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            As illustrated in Scheme 4, the saturated azetidine analogues would be synthesized in 
similar fashion to the unsaturated highly strained congeners from the alkylidenyl alcohol 36. 
Selective hydrogenation of the double bond of 36 would furnish the saturated azetidine 
analogues.  This selective hydrogenation is predicted to occur in high yield due to the relief of 
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ring strain induced by saturation of the double bond.  The saturated azetidine alcohol 38 will be 
furnished in a straightforward manner from 36, which is readily obtained from azetidinone 37 
(Scheme 3).  The alcohol 38 in turn will be subjected to a straightforward ether synthesis with 
the appropriately substituted benzhydryl derivative, which will provide the target 
diphenylmethoxyalkyl-N-substituted-azetidine analogues 30. 
 
Scheme 4.  Retrosynthesis of Saturated Azetidine Analouges 
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Construction of Azetidine Ring Systems 
           The challenge of synthesizing azetidine compounds has been attempted with some success 
by various other groups. 50-53 Figure 4 shows several of these azetidine derivatives that have been 
recently synthesized.  Interestingly, the diphenylmethyl azetidine analogue 39 has been reported 
to be very stable when stored in the refrigerator for several weeks.50 The stability is thought to be 
derived from the two phenyl moieties delocalizing the electron density from the nitrogen atom as 
well as steric interactions. This is believed to stabilize the strained ring system.  
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Figure 4.  Important Azetidine Derivatives 
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The few methods that are available for the synthesis of azetidines are somewhat tedious, 
limited in scope and low yielding.  Of these methods, the procedure developed by Higgins et 
al51seemed to be one of the most versatile and highest yielding (Scheme 5).  It was reported that 
starting with epichlorohydrin and benzylamine,  epoxide ring opening occurred to give aminal 42 
in moderate yield after two days at room temperature.  Following the ring opening, the azetidinol 
43 was formed in a modest yield by heating at reflux for three days.  It was reported that the 
yield of the azetidinol 43 could be increased by protection of the alcohol as the trimethylsilyl 
ether 44.  Subsequent treatment of 44 in refluxing petroleum ether after three days furnished the 
protected azetidine 45 in 35% yield.  The silyl ether 45 could then be deprotected with acid to 
give the azetidinol in a greater yield and higher purity. 
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Scheme 5.  Synthesis of Azetindinol 43 
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           An elegant synthesis to obtain the key azetidine 37 was recently reported by De Kimpe et 
al.54 The intermediate would set the stage for further reaction to obtain the target azetidine 
analogues.  As illustrated in Scheme 6, the azetidinone 37 would be unmasked from the 
protected ketal 46.  The azetidine ring would be formed via a reductive condensation process that 
proceeds through imine 47 from reaction of the appropriate aldehyde and the 
tribromopropylamine 48. 
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Scheme 6.  Retrosynthesis of Azetidinone 37 
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            De Kimpe et al. initiated the synthesis of azetidinone 37 by condensation of readily 
available starting material 48 and benzaldehyde at room temperature under basic conditions 
(Scheme 7).  Magnesium sulfate was used to scavenge the water that is produced and drive the 
reaction to completion.  After purification, the imine 47 was reduced with sodium borohydride 
and subsequent ring-closure insued.  Displacement of the bromines via methanolysis in refluxing 
methanol produced the protected ketal 46 in 52% yield over 3 steps.  This set the stage for 
unmasking the ketone by methyl ether cleavage with 10 equivalents of concentrated sulfuric acid 
for three hours followed by a basic workup.  De Kimpe reported the synthesis to afford the 
azetidinone 37 in 63% yield.  It was also noted that the azetidinone 37 starts to decompose at 
room temperature after eight hours and electron-withdrawing or sterically demanding 
substituents on the nitrogen atom stabilize the azetidinone from self-condensation.54  
 
 
 
 
  
 
33 
Scheme 7.  Synthesis of Azetidinone 37 
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Based upon the rational described above and the chemistry outlined, the synthesis of the 
target GBR-related compounds—GBR-tropane hybrids (Figure 1) and GBR-related azetidines 
(Figure 2) were pursued. 
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Results and Discussion 
 
GBR 12909-Tropane Hybrids: Synthesis of 8-Alkyl-3-diarylmethoxyethylidenyl-8-
azabicyclo[3.2.1]octane Analogues 
             The synthesis of the 8-alkyl-3-diarylmethoxyethylidenyl-8-azabicyclo[3.2.1]octane 
analogues commenced with the protection of the nitrogen atom of 3-tropinone (35).  It was 
envisaged that the basicity of the nitrogen atom could cause complications with further base 
promoted reactions.  As such, the carbamate 49 was prepared.  Three equivalents of ethyl 
chloroformate were used to make the carbamate 49 by refluxing in toluene overnight with 3-
tropinone under a nitrogen atmosphere.  Three equivalents of potassium carbonate were used to 
keep the reaction media basic and to help scavenge any excess hydrochloric acid that would be 
generated during the reaction.  After a standard workup and purification, the product 49 was 
obtained in 98% on a multigram scale (Scheme 8).  The carbamate 49 was subjected to 
Masamune-Roush modification of the Horner-Wadsworth-Emmons reaction.55 Normal 
olefination reactions usually undergo Wittig reaction conditions whereby an alkylphosphonate is 
treated with a strong base and added to the carbonyl compound.  Wittig reagents are usually very 
reactive and require low temperatures to produce high yielding reactions.  Under Masamune-
Roush-Horner-Wadsworth-Emmons conditions, the reactions are much cleaner, can be 
performed at room temperature and yield the olefination products in high yields.  Trimethyl-
phosphonoacetate was added to a stirred solution of lithium chloride in acetonitrile at room 
temperature.  The hindered base, 1, 8-diazabicylo[5.4.0]undec-7-ene (DBU), was added to the 
stirred solution followed by the carbamate 49 in acetonitrile.  It was important to add the 
reagents in the proper order starting with lithium chloride coordination with the phosphonate to 
increase the acidity of the -proton of the phosphonate and subsequently making the reagent 
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more reactive at room temperature.  The reaction was allowed to stir at room temperature 
overnight under an atmosphere of nitrogen.  After a standard workup and column 
chromatography, the alkene 34 was produced in 87% yield.  
 
Scheme 8.  Synthesis of Tropane Analogues 
N
O
N
O
O
EtO N
O
EtO
O
O
N
O
O
EtO
X
X
OH
O
EtO N
iii
iii
iv
X = H 59%
X = F  66%
35
49 34
33
50a
    b
Reagents:  i) EtOCOCl, K2CO3, toluene, .  ii) LiCl, (CH3O)2POCH2CO2CH3, DBU, CH3CN.
iii) LiAlH4, THF, 0
o C.  iv) (Ph)2CHCl or (4-F-Ph)2CHCl, neat, 145
o C.
98% 87%
89%
 
 
The reduction of the conjugated ester 34 had to be cautiously reacted with lithium 
aluminum hydride to yield the allyl alcohol 33.  Lithium aluminum hydride usually adds a 
hydride via 1,2-addition to reduce the ester to the alcohol.  However, in the presence of a 
conjugated ester such as 34, there is a potential for 1,4-addition of hydride to the double bond 
producing a mixture of side-products.  The conjugated ester was carefully added to a solution of 
1.2 equivalents of lithium aluminum hydride at 0° C via syringe over 30 minutes under a 
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nitrogen atmosphere.  After the addition of the ester was complete, the mixture continued to stir 
at 0° C.  After monitoring the reaction via TLC, it was determined that the reaction was complete 
after two hours.  The grey mixture was allowed to continue stirring at 0° C while a 10% KOH 
solution was very slowly added via syringe.  After the first drop of the 10% KOH solution was 
added, the reaction mixture bubbled profusely.  After the bubbles subsided, the reaction was 
slowly quenched and allowed to warm up to room temperature with stirring over one hour.  The 
mixture was poured into a separatory funnel and the white solid left in the flask was washed with 
diethyl ether.  The washings were added to the separatory funnel and phosphate buffer (pH = 7) 
was added.  After workup and purification, the allylic alcohol 33 was obtained in 89% yield. 
            The allylic alcohol 33 was then reacted with 1.5 equivalents of either chlorodiphenyl-
methane or bis(4-fluorophenyl)methylchloride to form the new benzhydryl ether derivative 50.  
The ether synthesis was performed neat at 145° C for two hours and no workup was required.  
After the reaction cooled to room temperature, it was dissolved in a minimal amount of ethyl 
acetate and put directly onto a column for purification.  The ether 50 was obtained in 59-66% 
yield. 
            The derivatized ether 50 was subjected to carbamate deprotection with refluxing 
hydrazine (Scheme 9).  Hydrazine monohydrate was added to the protected ether 50 in ethylene 
glycol followed by 26 equivalents of potassium hydroxide.  The mixture was stirred and brought 
to reflux for three hours.  The stability of the ether under such harsh conditions was initially 
uncertain, but under these basic conditions the ether remained intact.  After cooling to room 
temperature, the mixture was poured into a separatory funnel and washed with water.  Upon 
addition of water, the mixture turned a milky white but returned to a clear yellow solution after 
mixing with ether.  A standard workup and purification yielded the deprotected derivative 51 in 
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60-65% yield.  Further derivatization of the nitrogen atom of 51 ensued by reaction with the 
appropriate alkylbromide.  The reaction was carried out in DMF with 1.1 equivalents of the 
corresponding alkylbromide and 2.0 equivalents of potassium carbonate.  The reaction was 
stirred under a nitrogen atmosphere at 80 °C overnight.  The reaction was cooled to room 
temperature and a standard workup and purification yielded the various N-alkylated analogues 28 
in 45%-94%. 
 
Scheme 9.  Synthesis of Tropane Analogues 
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Resolution of 8-Alkyl-3-diarylmethoxyethylidenyl-8-azabicyclo[3.2.1]octane Analogues 
           It was of great interest to determine the structure-activity relationships of the resolved 8-
alkyl-3-diarylmethoxyethylidenyl-8-azabicyclo[3.2.1]octane analogues.  It was envisaged that 
one enantiomer would potentially be more potent and more selective at the dopamine transporter 
than the racemic mixture or the other enantiomer.  Enzymatic and kinetic resolutions were 
employed but yielded only starting material.  Exhaustive attempts to try to resolve the 
enantiomers by way of enzymatic and kinetic resolutions failed to resolve the allylic alcohol 33, 
vinylic ester 34, allylic ether 50 and nortropane 51. 
           The problem with trying to resolve these tropane analogues is the plane of symmetry that 
goes through the 8-azabicyclo[3.2.1.]octane ring system (Figure 5).  This results in a very small 
enantiomeric differentiation.  Initial attempts were made to resolve the allylic acetate ester 52 by 
enzymatic resolution with (PPL) porcine pancreatic lipase at 40° C to furnish the resolved ester  
[]20D = -1.36, c = 1.25 (Scheme 10).56  Only a small amount of starting material was resolved 
and this approach was abandoned.   
 
Figure 5.  Plane of Symmetry Through the Tropane Skeleton 
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Scheme 10.  Enzymatic Resolution with PPL 
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Derivatization of the vinylic carboxylic acid 53 with a menthol auxillary was attempted 
with the hope that the diastereomeric esters 54 could be separated by column chromatography or 
HPLC (Scheme 11).  Although the reaction to make the diastereomeric esters ensued in high 
yield, 85-97%, the mixtures proved inseparable by column chromatography or HPLC.  
Derivatization of the allylic alcohol 33 with different menthol or camphor auxillaries was also 
attempted.  The corresponding carbamates were obtained in 61-76% yield; however, these 
diastereomeric esters 55 were found to be inseparable as well (Scheme 12). 
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Scheme 11.  Carboxylate Ester Derivatization 
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Scheme 12.  Allylic Carbonate Ester Derivatization 
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Another attempt to resolve the enantiomers employed the Sharpless epoxidation of the 
allylic alcohol 33. It was envisaged that the Sharpless epoxidation would kinetically epoxidize 
one alcohol before the other (Scheme 13) giving the epoxide 56 and the resolved allylic alcohol 
33.  All the attempts to resolve the alcohol by Sharpless epoxidation failed and only starting 
material was recovered. 
 
Scheme 13.   Sharpless Epoxidation 
N
OH
CO2Et
N
OH
CO2Et
N
OH
CO2Et
O
+
Reagents:  i) Ti(OiPr)4, (+)-diethyl-tartrate, t-butyl hydrogen peroxide,
molecular sieves, CH2Cl2, -20
o C, overnight.
i
X
33
33 56
 
 
            After all attempts to kinetically resolve the enantiomers failed, it was envisaged that 
resolution might be achieved by making a diastereomeric salt.  Theoretically, one diasteromeric 
salt would crystallize better than the other, leaving the other diastereomeric salt in solution.  
Filtering the salt followed by freebasing the single diastereomeric salt would give the resolved 
alkylidenyltropane derivatives (Scheme 14).  This approach, although potentially tedious since 
each final analogue would have to be resolved, did offer the advantage that the enantiomers 
could be resolved on a multigram scale without the need for column chromatography.  In 
addition, the crystalline diastereomeric salt could be used to determine the absolute confirmation 
of the alkylidene by X-ray crystallography. 
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Scheme 14.  Salt Formation  
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            Many attempts to resolve any of the N-alkylidenyltropane analogues 28 by making a 
diastreomeric salt failed.  Many chiral acids were used in attempts to make these salts.  These 
included (+)-or (-)-mandelic acid and (+)-or (-)-tartaric acid.  Finally, the N-benzyl desfluoro 
analogue 28a was the only structure that was readily resolved (Scheme 15).  The salt of (-)-L-
dibenzoyl tartaric acid crystallized as the diastereomeric salt and resolved the tropane derivatives 
into the corresponding enantiomers. 
           The N-benzyl desfluoro analogue 28a was dissolved in dry methanol and allowed to stir at 
room temperature.  An equivalent of the L-or D-dibenzoyl tartaric acid was dissolved in dry 
methanol and added to the reaction flask.  After stirring for several minutes at room temperature, 
a white precipitate persisted and the solution was allowed to stir at room temperature for an 
additional five hours.  The precipitate was collected by vacuum filtration and the filtrate was 
concentrated under reduced pressure.  The residue from the filtrate was freebased with 
ammonium hydroxide and extracted with chloroform.  The organic layer concentrated and 
dissolved in dry methanol and subjected to resolution with the other chiral tartaric acid.  The 
salts were combined in a flask and freebased with ammonium hydroxide.  The freebase of the 
resolved analogue was separated from the aqueous layer with chloroform.  The organic layer was 
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evaporated and optical rotations determined as []20D = -17.5 and []20D = +17.0.  The 
enantiomers in Scheme 15 are ambiguously drawn for simplicity and do not represent the 
absolute stereochemistry of the resolved enantiomers.   The absolute stereochemistry will be 
determined via X-ray crystallography. 
 
Scheme 15.  Resolution of Tropane Analogue 28Ha 
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Reagents:  i) (-)-dibenzoyl-L-tartaric acid, MeOH, rt.  ii) NH4OH.
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*Compounds (+)-28Ha and (-)-28Ha are drawn for clarity but do not represent 
   the absolute configurations of the enantiomers.  
 
           Now that the alkylidene analogues could be resolved, it was thought that simply cleaving 
the ether in refluxing hydrochloric acid would afford the allylic alcohol 48.  The alcohol could be 
derivatized with bis(4-fluorophenyl)methylchloride to produce the 4-fluoro substituted 
benzhydryl moiety (Scheme 16). Debenzylation of the nitrogen could have been carried out with 
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a simple hydrogenation using 10% Pd/C; however, the presence of the double bond eliminated 
use of that transformation.  Other means of debenzylation would have to be found. 
 
Scheme 16.  Ether Derivatization 
N
O
N
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N
O
F
F
57
Reagents:  i) HCl, MeOH, .  ii) bis(4-fluorophenyl)methylchloride, neat, 145 oC
i
ii
28Ha
(+)-28Fa
60%
80%
 
 
The resolved N-benzyl desfluoro 28Ha compound was initially refluxed in 6M HCl, but 
the compound was not readily soluble in aqueous acid.  Dissolving the compound in methanol 
followed by refluxing in 6M HCl only produced starting material after a basic workup.  Finally, 
the resolved analogue 28Ha was dissolved in methanol and refluxed with concentrated 
hydrochloric acid overnight.  The solution was concentrated under reduced pressure and the 
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aqueous solution was chilled on an ice bath.  The pH was adjusted to pH = 12 with the slow 
addition of ammonium hydroxide and extracted with CH2Cl2 to yield the allylic alcohol 57 in 
60% yield.  The alcohol (57) was derivatized with the appropriate benzhydryl moiety as 
mentioned previously to give 28Fa to set the stage for debenzylation and further derivatization of 
the resolved analogues. 
            Attempts at nitrogen atom demethylation have been achieved with the addition of a 
carbamate in the initial nitrogen atom protection of 3-tropinone 35 described herein (Scheme 8).  
It was envisaged that debenzylation would work in the same fashion and deprotection would 
again produce the nortropane 51 (Figure 6).   
 
Figure 6.  Attempted Nitrogen Atom Debenzylation 
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            The N-benzyl difluoro analogue 28a was subjected to debenzylation with three 
equivalents of ethylchloroformate and three equivalents K2CO3 in refluxing toluene overnight.   
After a standard workup, the reaction yielded only starting material.  A stronger, more reactive 
carbamate might be more successful at debenzylation.  After a thorough search of the literature, 
the very reactive -chloroethylchloroformate, ACE-Cl, was identified as a potential reagent for 
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debenzylation of the nitrogen atom.  However, after several attempts at room temperature and 
under refluxing conditions, only starting material was recovered or total decomposition of the 
resolved compound 28Fa occurred.   
            Although very reactive, ACE-Cl should have been able to debenzylate the nitrogen.  
However, there could be some steric interactions that keep the benzylic carbon atom from 
nucleophilic attack (Figure 7).   Because the benzyl moiety is most likely oriented to the back of 
the tropane ring, subsequent nucleophilic attack of chloride to release the carbamate intermediate 
is hindered by the phenyl ring and the tropane skeleton.  As a result, the reaction cannot proceed 
further and leads either to recovery of starting material after workup or decomposition. 
 
Figure 7. Steric Interference from Tropane Ring and Substituents 
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            Other attempts of debenzylation were investigated.  It was thought that by selective 
oxidation at the benzyl position with potassium permanganate would install a carbonyl 
functionality 58.  The subsequent amide would be more reactive to deamidation with hydrazine 
in refluxing ethylene glycol.   
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             The N-benzyl difluoro analogue 28 was subjected to oxidation with three equivalents 
KMnO4 overnight at room temperature.  After workup, the amide 58 was refluxed with five 
equivalents hydrazine monohydrate, 25 equivalents KOH in ethylene glycol for three hours.  
However, NMR spectra showed only starting material (+)-28Fa.  Attempts to debenzylate the 
nitrogen atom were abandoned at this point. 
N
O
F
F
N
O
F
F
O
58
(+)-28a
 
 
Attempted Synthesis of 3-Diphenylmethoxyalkyl-8-substituted-azetidine Analogues 
             The synthesis of the 3-diphenylmethoxyalkyl-8-substituted-azetidine analogues 
commenced with the readily available benzylamine and epichlorohydrin (Scheme 17).  
Benzylamine was added to a reaction flask and dissolved in water.  Epichlorohydrine was added 
dropwise at 0 °C and the mixture was allowed to stir at room temperature for 3 hours.  After 
adjusting the pH = 14, the mixture was subjected to a standard workup and the chlorohydrin 42 
was isolated in 90% yield.  The chlorohydrin 42 was dissolved in dichloromethane and brought 
to reflux for 3 days to generate the azetidine.  However, after following the reaction via NMR, 
the azetidinol 43 was not being formed. 
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Scheme 17.  Attempted Synthesis of Azetidinol 43 
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O
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Reagents;  i) H2O.  ii) CH2Cl2, Et3N,  3 days.
N
H
OH
 
 
            Another attempt to close the ring was made by reacting the alcohol 42 with trimethyl-
silylchloride (Scheme 18).  This would protect the alcohol from any potential nucleophilic attack 
with the chloride causing unwanted side-products.  The alcohol was dissolved in 
dichloromethane and two equivalents of triethylamine were added.  The mixture was brought to 
0 °C and trimethylsilylchloride was added dropwise via syringe.  The mixture was allowed to stir 
at room temperature for three hours under an atmosphere of nitrogen.  After a standard workup 
and purification via column chromatography, the silyl ether 44 was isolated in 63% yield.  
Refluxing for 48 hours in acetonitrile and triethylamine closed the ring giving the azetidinol 
ether 45 in 35% yield.  The silyl ether was removed with concentrated hydrochloric acid at room 
temperature for five minutes to give the azetidinol 43 in quantitative yield.  Many attempts were 
made to oxidize the alcohol to the azetidinone 37 with several oxidizing agents including Swern 
oxidation conditions and pyridinium dichromate.  However, all attempts failed due to the 
instability of the azetidinone, workup conditions or purification techniques.   
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Scheme 18.  Attempted Synthesis of Azetidinone 37 
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iii) CH3CN, Et3N, , 48 h.  iv) aq. HCl, rt, 5 min  v)[oxidation]
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Synthesis of 3-Diphenylmethoxyalkyl-8-substituted-azetidine Analogues 
            As illustrated in Scheme 19, the synthesis of the 3-diphenylmethoxyalkyl-8-substituted-
azetidine analogues commenced with the synthesis of the amine 61 from the commercially 
available starting materials hexemethylenetetramine 59 and 2, 3-dibromopropene 60.  The 
reaction is known as the Delepine reaction.56 To a three-neck flask fitted with an addition funnel 
and a condenser was added hexamethylentetramine in chloroform. The mixture was stirred using 
a Hershberg stirrer at reflux.  The alkene 60 was added slowly via the addition funnel over one 
hour and the reaction was allowed to reflux an additional three hours.  The reaction was then 
cooled to room temperature and allowed to stand overnight.  The white precipitate was filtered 
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via vacuum filtration, collected and allowed to air dry.  The product was acidified in ethanol, 
water and hydrochloric acid and allowed to stand at room temperature for 24 hours. 
 
Scheme 19.  Synthesis of Azetidinone 37 
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Reagents:  i) CHCl3, .  ii) EtOH, 12N HCl.  iii)  aq. HBr .  iv) Br2.
v) benzaldehyde, Et3N, benzene, BF3-Et2O, H2O, DST, .  vi) NaBH4,
MeOH, .  vii) H2SO4, NaOH.
6059
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85%
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              The ammonium chloride salt was filtered via vacuum filtration and the mother liquor 
concentrated to dryness.  This was dissolved in water and made basic to pH = 13.  After 
extracting the aqueous layer with ether, the amine 61 was collected and distilled under reduced 
pressure in 81% yield.  The amine 61 was dissolved in water and acidified to pH = 1 with 48% 
HBr.  The amine was protected as the salt to keep it from reacting with itself or the bromine in 
the bromination step.  Bromine was then added dropwise to the amine in water and allowed to 
stir at room temperature overnight.  After concentrating the mixture under reduced pressure, the 
salt 48 was collected as an off-white solid in 85% yield. 
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             With the salt 48 in hand, this set the stage for derivatization and subsequent ring closure.  
Initially, the condensation of the amine 48 with the prospective aldehyde (i.e. benzaldehyde) was 
reacted at room temperature in dichloromethane.  The reaction is an equilibrium reaction that 
generates water.  The addition of magnesium sulfate was used to scavenge the water and drive 
the reaction to completion.  However, attempts at accomplishing this transformation in any 
appreciable yield were unsuccessful even under refluxing conditions. 
Because the reaction is an equilibrium reaction generating water, it was thought that 
azeotropic distillation with benzene would drive the reaction to completion forming the 
condensation product 47.  Benzene was added to the amine 48 then it was dissolved in water and 
triethylamine followed by the addition of benzaldehyde.  Initial reactions involving the 
condensation and removal of water were not successful.  Therefore, a catalytic amount of 
BF3•Et2O was added to promote the reaction by acting as a Lewis acid, which would coordinate 
to the aldehyde to make it more reactive.  After fitting the reaction flask with a Dean-Stark trap 
and condenser, the reaction was refluxed overnight.  After cooling the reaction mixture to room 
temperature, diethyl ether was added to precipitate the ammonium chloride salt.  The salt was 
filtered and the filtrate concentrated under reduced pressure to afford the crude imine 47. 
            Initially, the imine was purified via column chromatography giving 47 in 85-90% yield.   
However, it was decided that the instability of the imine under purification conditions might give 
lower yields.  Therefore, the imine was immediately dissolved in dry MeOH, placed under a 
nitrogen atmosphere and cooled to 0 °C.  Sodium borohydride was added to the solution portion 
wise over one hour.  With the addition of the reducing agent, the imine is reduced and 
subsequent ring closure of the amine occurs.  Several attempts were tried in which the sodium 
borohydride was added at room temperature in one addition or in larger portions than previously 
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describe, however, these attempts produced lower yields.  After the final addition of the reducing 
agent, the reaction was allowed to come to room temperature and then refluxed overnight.   
During the course of the reaction, there are three transformations occurring:  (1) the imine 
reduction, (2) the ring closure and (3) the nucleophilic substitution with methanol (Figure 8).  
When the azetidine is formed, the ketal protecting group prevents the ring from decomposing or 
self-condensation.   
 
Figure 8.  Azetidine Ketal Formation 
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            After all the water was collected and removed, the reaction was cooled to room 
temperature.  The benzene was removed under reduced pressure and a standard workup ensued.  
The crude mixture was subjected to purification via column chromatography furnishing the 
azetidine 46 in 41-51% yield over four steps. 
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            The azetidine was dried under vacuum to remove all traces of water.  Initial attempts to 
deprotect the azetidine under aqueous conditions failed and only starting material was recovered.  
Standard acetal or ketal deprotection is performed in aqueous medium with a catalytic amount of 
the acid.  The deprotection to aquire the azetidinone 37 was performed in water with a catalytic 
amount of concentrated sulfuric acid at room temperature overnight.  After adjusting the pH = 
12, the aqueous layer was extracted with dichloromethane to yield only starting material.   
            Treatment again of the ketal with water and 10 equivalents of concentrated sulfuric acid 
at room temperature overnight proved unreactive.  The acidic solution was then refluxed for 
several hours but only starting material was acquired.  As a last resort, the ketal was thoroughly 
dried under reduced pressure to remove all traces of water.  The ketal was put on an ice water 
bath to lower the temperature to 0 °C.  Concentrated sulfuric acid was added drop wise to the 
flask until all 10 equivalents were added.  The reaction was allowed to stir at room temperature 
and the reaction was followed by NMR spectroscopy.  After three hours, total transformation of 
the ketal to the azetidinone 37 was complete.  The reaction was chilled again on an ice water 
bath and the temperature reduced to 0 °C.  Saturated NaOH was added slowly to the reaction 
until a pH = 12 was reached.  The mixture was taken up in water and extracted with 
dichloromethane.   
The azetidinone 37 is highly unstable at room temperature and starts to decompose.54, 58 
Therefore, during the workup of the azetidinone, the solvent was concentrated under reduced 
pressure with no heat.  Further, because of the instability of the newly formed ketone, column 
chromatography could not be used to purify the product.  Fortunately, the azetidinone was pure 
enough by NMR spectroscopy to be carried forward to the next step as illustrated in Scheme 20. 
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Scheme 20.   Synthesis of Alcohols 36 and 38 
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            Following Masamune-Roush-Horner-Wadsworth-Emmons conditions, LiCl was stirred 
in acetonitrile.  Trimethylphosphonoacetate was added followed by DBU.  When the mixture is 
not performed in that order, the product of olefination is achieved in much lower yields.  
Following the addition, the azetidinone 37 was added as a solution in acetonitrile straight from 
the previous deprotection reaction.  The olefination reaction is done under an atmosphere of 
nitrogen and in dry acetonitrile.  Because the azetidinone from the previous reaction is worked 
up in water and is too unstable to leave on a drying pump for an extended amount of time, the 
absolute exclusion of water was unavoidable.  Nevertheless, the reaction was stirred at room 
temperature overnight and the olefination product 62 was isolated after a standard workup and 
column chromatography in 55% yield over two steps from the ketal 46. 
             The conjugated ester 62 was taken up in THF and subjected to reduction to the allylic 
alcohol 36 with LiAlH4 or reduced to the saturated ester 63 with 10% Pd/C under a hydrogen 
atmosphere.   The ester 62 was reduced at 0 °C for two hours and quenched with 10% NaOH.  
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After workup, the crude allylic alcohol 36 in 89% was identified via NMR spectroscopy along 
with approximately 10% of a saturated side product.  Because of the reactivity of the conjugated 
ester 62, the reaction proceeds at low temperatures to prevent the formation of any side products.  
However, every attempt to reduce the ester to the allylic alcohol was contaminated with 10-20% 
of the saturated 1, 4-addition product.  Further, attempts to purify the alcohol via column 
chromatography decreased the yield significantly.  Therefore, after workup, the crude mixture 
was used in the next step without any further purification. 
             The ester 62 was also subjected to hydrogenation with 10% Pd/ C under 1atm H2.  The 
resulting saturated ester 63 was filtered through a layer of Celite and collected.  After 
concentrating under reduced pressure, the ester 63 was pure via NMR spectroscopy in 89%.  The 
saturated ester was subjected to the same reduction conditions as the conjugated ester with 
LiAlH4 to afford the saturated alcohol 38 in 89% yield. 
The stability of the azetidine ring of the unsaturated analogues was of great importance 
when selecting the reaction to make the final product 29 and 30.  Several reactions were initially 
undertaken at lower temperatures to ensure the stability of the ring.  The preparation of the ether 
29 was initiated with the allylic alcohol and chlorodiphenylmethane in DMF at room temperature 
but was eventually heated to 80 °C overnight (Scheme 21).  However, the reaction did not 
proceed at this temperature.  Usually the reaction is performed at high temperatures (145-160° 
C).  
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Scheme 21.  Synthesis of Azetidine 29 
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            Another attempt was employed to afford the product formed via Wittig olefination.  
Unfortunately, the starting Wittig reagent was not commercially available and had to be prepared 
from diphenylmethanol and bromoethanol (Scheme 22). This would then be reacted with 
triphenylphophine or a trialkylphosphonate to produce the Wittig reagent.  This would in turn be 
reacted with the azetidinone to furnish the final product. 
Diphenylmethanol was condensed with 2-bromoethanol using a Dean-Stark trap to 
furnish the ether 65.  However, all attempts to make the phosphine reagent failed because the 
affinity of the phosphorous atom for the oxygen atom of the ether produced an unwanted side 
reaction instead of the desired phosphine reagent (Figure 9).  This route was abandoned and 
further investigations of reactions with the allylic alcohol were continued. 
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Scheme 22.  Retrosynthesis of 29  
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Figure 9.  Side Reaction with Triphenylphosphine 
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             To make the reaction more reactive so it would proceed at room temperature, 
diphenylmethanol was treated with NaH and reacted with half an equivalent of TsCl.  The newly 
formed tosylate was added to a mixture of NaH and the allylic alcohol 36 and allowed to stir 
overnight.  After following the reaction via NMR spectroscopy, it was observed that the reaction 
was not proceeding at room temperature.  The reaction was slowly heated to 60 °C and the 
stability of the azetidine ring was observed via NMR spectroscopy to make sure it was still intact 
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at higher temperatures (Scheme 23).  The reaction was allowed to react overnight at 60 °C.  The 
mixture was then cooled to room temperature and quenched with water.  After workup, the 
product was only obtained in 58% crude yield. 
 
Scheme 23.  Attempted Azetidine Synthesis 
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            Because of the low yield produced from the previous procedure, other reaction conditions 
were investigated.  Following the reduction of the conjugated ester 62, the crude allylic alcohol 
36 was dissolved in benzene (Scheme 24).  To the solution was added p-toluenesulfonic acid 
(PTSA) and diphenylmethanol.  The flask was fitted with a Dean-Stark trap and refluxed (80 °C) 
overnight.  The reaction was concentrated under reduced pressure and following a standard 
workup and column chromatography, the product was obtained in 17% yield over two steps. 
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Scheme 24.  Final Step to Azetidine Analogues 
Reagents:  i) diphenylmethanol, PTSA, benzene, .
N
OH
N
O
i
36
29
17%
 
 
Biology: Dopamine, Serotonin and Norepinephrine Transporter Affinity of GBR 12909 
Tropane Hybrid Analogues 
            All final target compounds synthesized were tested as the oxalate salts.  Binding affinities 
for the dopamine, serotonin and norepinephrine transporters were determined by the ability of 
the drug to displace the radiolabeled ligands  [3H]WIN 35,428 (67, [3H]Citalopram (68), and 
[3H]Nisoxetine (69), respectively, from the monoamine transporters found in rat caudate-
putamen tissue.7, 12, 59  
            The binding affinities of all compounds listed in Table 1 were initially determined for the 
dopamine transporter.  The compounds that exhibited dopamine transporter binding affinities 
with values Ki < 100 nM were evaluated at the serotonin and norepinephrine transporters to 
determine transporter selectivity.  Those compounds that exhibited low binding affinity (Ki > 100 
nM) at dopamine transporters were typically not evaluated further. 
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            The racemic analogue 28Ha was fairly potent (DAT Ki = 48 nM, SERT/ DAT = 113) and 
selective for the dopamine transporter over the serotonin transporter.  However, the resolved 
analogues (+)-28Ha and (-)-28Ha varied, as expected, in the ability to displace the tritiated 
ligands from the appropriate monoamine transporters.  
N
CH3
CO2CH3
F
[3H]WIN 35,428
            67
O
N
F
H3CO
O
NHCH3
[3H]Citalopram
          68
[3H]Nisoxetine
          69
NC
 
Interestingly, (+)-28Ha was 3-fold more potent and more selective than the racemic 
mixture (DAT Ki = 16 nM, SERT/ DAT = 316).  Further, (+)-28Ha was 8-fold more potent and 
7-fold more selective for the dopamine transporter over the serotonin transporter than its 
enantiomer (-)-28Ha (DAT Ki = 134 nM, SERT/ DAT = 46) and it was also equipotent with 
GBR 12909 (DAT Ki = 12 nM, SERT/ DAT = 35).  The (-)-isomer (-)-28Ha was 3-fold less 
potent than the racemic mixture at the dopamine transporter and there was a 2.5-fold decrease in 
selectivity for the dopamine transporter over the serotonin transporter.  Although the 
stereoselectivity of the dopamine transporter of the enantiomeric form of 28Ha was not as 
dramatic as that observed for the stereoisomers of cocaine.13, 19 These results further illustrate the 
sensitivity of the dopamine transporter to stereochemical differences in ligand topology. 
            Given the modest difference in binding affinity between the stereoisomers of 28a the 
other analogues (28b-i) were tested as the unresolved mixture of racemates.  The desfluoro 
analogues 28Hb, 28Hc, 28Hd, 28He and 28Hf were found not to be very potent at the dopamine 
transporter.  The propyl analogue 28Hc (DAT Ki = 245 nM) was equipotent with the ethyl 
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analogue 28Hb (DAT Ki = 286 nM).  However, the allyl analogue 28He was more potent (DAT 
Ki = 143 nM) than the propyl analogue 28Hc.  Interstingly, the propargyl analogue 28Hd was 
less potent (DAT Ki = 536 nM) than either the propyl analogue 28Hc or the allyl analogue 28He.  
The cyclopropymethyl analogue 28Hf (DAT Ki = 169 nM) was also not very potent at the 
dopamine transporter. 
The 4-fluorophenyl analogues 28Fb-f were tested at the monoamine transporters and 
proved to be more potent than the desfluoro analogues 28Hb-f.  The ethyl 28Fb (DAT Ki = 40 
nM) and propyl 28Fc (DAT Ki = 41 nM) analogues proved to be equipotent but 6- to 7-fold more 
potent than their desfluoro analogues.  This follows the trend that the 4-fluorophenyl analogues 
are more potent than the desfluoro analogues.  Further, the allyl analogue 28Fe (DAT Ki = 21 
nM) was twice as potent as the ethyl and the propyl analogues 28Fb, c.  Interestingly, the 
cyclopropylmethyl analogue 28Ff (DAT Ki = 4 nM, SERT/ DAT = 1060) was 3-fold more 
potent than GBR 12909 and greater than 30-fold more selective for the dopamine transporter 
over the serotonin transporter.  This is the most selective dopamine transporter ligand 
synthesized to date from these laboratories. 
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Table 1.  Inhibition of [3H] WIN 35,428, [3H] Citalopram and  [3H] Nisoxetine 
N
O
X
X
R
28
 
 
Cmpda X R DATb 
 (Ki, nM) 
SERTb 
(Ki, nM) 
NET 
(Ki, nM) 
SERT/DAT   NET/ DAT 
GBR12909 
28Ha 
28Ha-(+) 
28Ha-(-) 
28Fa 
28Hb 
 
H 
H 
H 
F 
H 
 
Bn 
Bn 
Bn 
Bn 
Et 
12 ± 1.9 
48 ± 5.0 
16 ± 3.0 
134 ± 6.0 
7.9 ± 0.5 
286 ± 25 
 
5420 ± 74 
5059 ±820 
6143 ± 1529 
2220 ± 740 
 
1393 ± 147 
1200 ± 168 
2261 ± 463 
 
2430 ± 560 
28Fb F Et 40 ± 3.0 5958 ± 786 3577 ± 117 
     35 
    113                29   
    316                75 
      46                17 
     281                  
                           8 
149              89 
28Hc H Pr 245 ± 20  2087 ± 335                             9      
28Fc F Pr 41 ± 7.7 5463 ± 318 2847 ± 349 133               69 
28He H CH2CH=CH2 143 ± 15  1740 ± 335                            12 
28Fe F CH2CH=CH2 21 ± 2 3461 ± 314 3120 ± 669 167              149 
28Hd H CH2CCH 536 ± 49    
28Fd F CH2CCH NAc    
28Hf H CH2Cp 169 ± 44    
28Ff F CH2Cp 4.0 ± 2.7 4239 ± 225  1060              
28Hg H 4-F-Bn 7.0 ± 1.9 4094 ± 1528 2219 ± 543d 585             317 
28Fg F 4-F-Bn 4.9 ± 1.3 1145 ± 144 3270 ± 127d 234             654 
28Hh H 4-Cl-Bn 7.6 ± 1.0 544 ± 89 2827 ± 222d 72             372 
28Fh F 4-Cl-Bn 3.9 ± 2.0 656 ± 193 4974 ± 948d 168            1244 
28Hi H 4-CH3-Bn     13 ± 2.0 746 ± 192 2132 ± 18
d 57             164 
28Fi F 4-CH3-Bn 6.1 ± 1.1 405 ± 98 3663
4 68             611 
a) All compounds were tested as the oxalate salts. 
b) All values are the mean ± (SEM) of three experiments preformed in triplicate. 
c) The compound decomposed and a reliable Ki value could not be obtained. 
d) All values are the mean ± (SEM) of three experiments performed in duplicate. 
e) All values are the mean ± (SEM) of three experiments. 
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            The N-4-substituted-benzyl analogues 28Hh-i and 28Fh-i were tested at the monoamine 
transporters and were generally found to be more potent than GBR 12909.  The N-(4-
fluorobenzyl) analogue 28Hg (DAT Ki = 7 nM, SERT/ DAT = 585) was more potent than GBR 
12909 and more selective for the dopamine transporter over the serotonin transporter than the 
other analogues in this series.  The N-(4-fluorobenzyl)-bis(4-fluorophenyl) analogue 28Fg (DAT 
Ki = 4.9 nM, SERT/ DAT = 234) was equipotent with its conformer but was about 2-fold less 
selective for the dopamine transporter over the serotonin transporter.  Further, the N-(4-
fluorobenzyl) analogues 28Hg and 28Fg were more selective for the dopamine transporter over 
the norepinephrine transporter. 
            The N-(4-chlorobenzyl) analogues 28Hh (DAT Ki = 7.6 nM, SERT/ DAT = 72) and 
28Fh (DAT Ki = 3.9 nM, SERT/ DAT = 168) were more potent than GBR 12909 (DAT Ki = 12 
nM, SERT/ DAT = 35) and more selective for the dopamine transporter over the serotonin 
transporter.  However, as the lipophilicity of the substituent on the N-benzyl group (Table 2) was 
increased, generally, there was a decrease in selectivity for the dopamine transporter over the 
serotonin transporter.  This was due to increased serotonin transporter affinity. The N-(4-
methylbenzyl) analogues 28Hi (DAT Ki = 13 nM, SERT/ DAT = 57) and 28Fi (DAT Ki = 6.1 
nM, SERT/ DAT = 68) were the least potent in the series but were equipotent or more potent 
than GBR 12909.  Further, the N-(4-chlorobenzyl) analogues 28Hh and 28Fh and the N-(4-
methylbenzyl) analogues 28Hi and 28Fi were more selective for the dopamine transporter over 
the norepinephrine transporter.  The N-(4-chlorobenzyl) analogue 28Fh (NET/ DAT = 1244) was 
the most selective ligand for the dopamine transporter over the norepinephrine transporter in the 
series. 
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Table 2. clogP values of N-4-Substituted Benzyl Analogues 28g-i 
Cmpd clogP 
28Hg 6.44 
6.72 28Fg 
28Hh 7.01 
28Fh 
28Hi 
28Fi 
7.29 
6.79 
7.08 
 
             The tropane hybrid alkylidene analogues are more structurally rigid than GBR 12909. 
The bicyclic tropane ring system and the double bond decrease the flexability of the analogues 
unlike the piperazine ring system of GBR 12909.  However, the similarities to GBR 12909 are 
the benzhydryl ether moiety and substitution of the distal nitrogen atom.  The tropane hybrid 
analogues 28a-i have, generally, been more selective than GBR 12909 for the dopamine 
transporter over the serotonin transporter. 
            Substitution of an N-benzyl or N-alkyl moiety at the nitrogen atom of the tropane hybrid 
analogues has demonstrated differences in binding at the dopamine transporter.   Overall, the N-
benzyl analogues were more potent than the N-alkyl analogues at the dopamine transporter.  
However, the N-cyclopropylmethyl analogue 28Ff was equipotent with several of the N-benzyl 
analogues but was the most selective ligand in the series for the dopamine transporter over the 
serotonin transporter. 
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            The structure-activity relationship of the N-4-substitutedbenzyl analogues demonstrated 
differences in potency at the dopamine transporter and selectivity for the dopamine transporter 
over the serotonin and norepinephrine transporters.  The potency increased at the dopamine 
transporter as the lipophilicity of the N-para-substituted-benzyl analogue increased.  The trend 
for increased potency at the dopamine transporter was Cl > F > CH3 > H.  The N-4-chlorobenzyl 
analogues 28Hh (clogP = 7.01) and 28Fh (clogP = 7.30) were the most lipophilic analogues of 
their class.  The N-4-chlorobenzyl analogue 28Fh (DAT Ki = 4.0 nM) was the most potent N-4-
substitutedbenzyl analogue of the series.  
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Conclusions 
            A series of GBR 12909-tropane analogues were synthesized and evaluated at the 
dopamine, serotonin and norepinephrine transporters.  In general, the tropane hybrid analogues 
(28Ha, 28Fb-i) were potent at the dopamine transporter. Several of the GBR 12909-tropane 
hybrid analogues proved to be more potent at the dopamine transporter and more selective over 
the serotonin transporter than GBR 12909.  An enantiomeric resolution of the tropane analogue 
28Ha has been developed on a multigram scale.  The dopamine transporter binding affinity of 
the resolved N-benzyl tropane analogue (+)-28Ha further demonstrated a stereochemical 
sensitivity for ligand binding at the dopamine transporter.  The resolved enantiomer (+)-28Ha 
was equipotent with GBR12909 and more than 3-fold more selective for the dopamine 
transporter over the serotonin transporter.  Further, the fluoro-substituted analogues are more 
potent than the desfluoro analogues.  The N-benzyl tropane analogues are more potent than the 
N-alkyl tropane analogues.  However, the N-cyclopropylmethyl tropane analogue 28Ff (DAT Ki 
= 4 nM, SERT/ DAT = 1060) proved to be the most selective dopamine transporter ligand that 
has been synthesized in these laboratories to date.   
            A novel synthesis of several GBR12909 azetidine hybrid analogues was developed.  The 
rationale for the synthesis of these novel azetidine analogues was to decrease the lipophilicity of 
the compound while maintaining the structural rigidity.  This will potentially increase the 
bioavailability of the compound without decreasing the potency at the dopamine transporter.  
These novel GBR 12909 azetidine hybrid analogues are currently being tested at the dopamine, 
serotonin and norepinephrine transporters and the biological data will be reported in due course. 
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Experimental 
General Experimental Methods 
            All chemicals were purchased from Aldrich Chemical Company and used as received 
unless otherwise noted.  Anhydrous toluene, dichloromethane (CH2Cl2), methanol (MeOH), 
chloroform (CHCl3), tetrahydrofuran (THF) and acetonitrile (CH3CN) were purchased from 
Mallinckrodt Baker, Inc.  Thin layer chromatography (TLC) 20  20 cm glass plates precoated 
with 250 μm silica gel were purchased from Sorbent Technologies and used to monitor reactions 
via visualization with short-wave UV light, iodine, potassium permanganate, 2,4 dinitrophenyl 
hydrazine or Dragondorff’s reagent.  Chromatography was performed over Sorbent Technologies 
silica gel 60 angstrom (230-400 mesh).  High-pressure hydrogenations were carried out on a Parr 
apparatus.  Proton and carbon NMR were recorded on a Varian-400 MHz nuclear magnetic 
resonance spectrometer at ambient temperature in deuterated chloroform, acetone or water from 
Cambridge Isotope Laboratories, Inc.  1H NMR chemical shifts are reported as  values (ppm) 
relative to tetramethylsilane.  Splitting patterns are designated as: s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet.  13C NMR chemical shifts are reported as  values (ppm) 
relative to chloroform-d (77.0 ppm).  Optical rotations were measured on Autopol III 
autopolarimeter at the sodium D line (2 mL sample cell).  Melting points (m.p.) were measured 
with an Electrothermal  Mel-Temp apparatus and are uncorrected. 
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N-Ethoxycarbonyl-8-azabicyclo[3.2.1.]octan-3-one  (49) 
In a clean, dry 500 mL round-bottom flask was added a stir-bar, 3-tropinone (10.0 g, 72 
mmol) and K2CO3 (50 mg).  Freshly distilled toluene (90 mL) was added followed by 3 
equivalents of ethylchloroformate (21 mL, 220 mmol) via syringe, drop wise.  The flask was 
fitted with a condenser, nitrogen bubbler and refluxed overnight with stirring.  The reaction was 
concentrated under vacuum and the brown oil was dissolved in CH2Cl2 (100 mL) and washed 
with H2O (100 mL).  The layers were separated in a separatory funnel and the aqueous layer 
extracted with CH2Cl2 (3  50 mL).  The organics were combined and dried over Na2SO4, filtered 
and concentrated under vacuum.  The residue was purified by column chromatography (SiO2, 
EtOAc/ hexane, 1:3) to produce 13.1 g, 92% of a light yellow oil. 1H NMR (400 MHz CDCl3)  
4.51 (bs, 2H), 4.16 (q, J = 7.2 Hz, 2H), 2.63 (bs, 2H), 2.31 (dd, J = 17.4, 1.6 Hz, 2H), 2.07-2.03 
(m, 2H), 1.65 (d, J = 7.6 Hz, 2H), 1.25 (t, J = 7.2 Hz, 3H). 13C NMR (400 MHz CDCl3)  208.3, 
154.1, 61.6, 53.2, 49.1, 29.5(2), 28.8(2), 14.9.63 
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N-Ethoxycarbonyl-3-methoxycarboethylidenyl-8-azabicyclo[3.2.1.]octane (34) 
To a clean, dry 500 mL round-bottom flask was added 1.2 equivalents (3.4 g, 80 mmol) 
LiCl and a stir bar and sealed under a nitrogen balloon.  Acetonitrile (180 mL) was added 
followed by 1.2 equivalents of trimethylphosphonoacetate (6.04 mL, 37 mmol).  The mixture 
was allowed to stir at room temperature for 30 minutes to dissolve the LiCl.  DBU (4.60 mL, 31 
mmol) was added via syringe, drop wise, over 10 minutes.  The protected tropinone 49 (13.1 g, 
66 mmol) was dissolved in CH3CN (60 mL) and syringed into the flask.  The mixture was all 
allowed to stir at room temperature overnight under N2.  The reaction was concentrated under 
reduced pressure and the light brown oil was dissolved in CH2Cl2 (100 mL) and washed with 
H2O (50 mL). The layers were separated in a separatory funnel and the aqeuous layer was 
extracted with CH2Cl2 (3  50 mL).  The organics were combined and dried over Na2SO4, filtered 
and concentrated under vacuum.  The residue was purified by column chromatography (SiO2, 
EtOAc/ hexane, 1:4) to produce 14.5 g, 87% of a light yellow oil.  1H NMR:  5.79 (s, 1H), 4.39 
(brs, 2H), 4.19 (t, J = 6.8 Hz, 2H), 3.69 (s, 3H), 2.69 (brs, 1H), 2.36 (brs, 1H), 2.12 (d, J = 14.4 
Hz, 1H), 1.94 (s, 2H), 1.59 (d, J = 7.2 Hz, 2H), 1.28 (t, J = 6.8 Hz, 4H).  13C NMR:  165.6, 
155.2, 153.2, 118.2, 60.4, 53.6, 53.4, 50.3, 42.1, 35.5, 27.9(2), 14.2.  Anal. Calc. for C13H19NO4:  
C, 61.64; H, 7.56; N, 5.53.  Found:  C, 61.46; H, 7.66; N, 5.48.  NMR data is comparable to 
reference 64. 
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N-Ethoxycarbonyl-3-hydroxymethylethylidenyl-8-azabicyclo[3.2.1.]octane (33) 
Lithium aluminum hydride (1.2 equivalents, 870 mg, 23 mmol) and a stir bar were added 
to a clean, dry 250 mL round-bottom flask and sealed under a nitrogen balloon. THF (35 mL) 
was added via syringe and the solution brought to 0°C in an ice-water bath.  The ester (3.85 g, 15 
mmol) was dissolved in THF (15 mL) and added drop wise over 20 minutes via syringe. The 
reaction was stirred at 0 °C for 1.5 hours and quenched by the slow addition of 10% KOH (11 
mL).  Stirring was continued for an additional hour and the reaction mixture was decanted into a 
separatory funnel.  The white solid was washed with diethyl ether (4  30 mL) and the organics 
added to the seperatory funnel.  The organics were washed with phosphate buffer (75 mL) and 
the buffer extracted with diethyl ether (4  30 mL).  The organics were dried over Na2SO4, 
filtered and concentrated under reduced pressure.  The resulting alcohol was purified by column 
chromatography (SiO2, EtOAc/ hexane, 1:1) to yield 3.0 g, 89% of a light yellow oil.  
1H NMR: 
 5.58 (m, 1H), 4.32 (s, 2H), 4.16 (m, 4H), 2.53 (d, J = 13.6 Hz, 2H), 2.41(d, J = 14 Hz, 2H), 
2.23 (d, J = 14.4 Hz, 2H), 2.03 (d, J = 13.6 Hz, 2H), 1.89 (m, 3H), 1.61 (t, J = 7.6 Hz, 2H), 1.52 
(t, J = 7.6 Hz, 2H).  13C NMR:  153.7, 134.4, 127.7, 60.7, 57.7, 53.6, 41.6, 34.5(2), 27.8(2), 
14.3.  Anal. Calc. for C12H19NO3:  C, 63.97; H, 8.50; N, 6.22.  Found:  C, 63.76; H, 8.61; N, 6.43. 
NMR data is comparable to reference 64. 
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3-(2-Diarylmethoxy-ethylidene)- N-ethoxycarbonyl-8-azabicyclo[3.2.1]octane (50a) 
            In a clean, dry 10 mL round-bottom flask was added the alcohol (1.1 g, 5 mmol), bis-4-
fluorophenylmethylchloride or chlorodiphenylmethane (1.5 equivalents, 1.30 mL, 7 mmol) and a 
stir bar.  This was heated neat to 145 °C for 2 hours under N2.  The reaction was cooled to room 
temperature, dissolved in pure ethyl acetate and purified immediately by column 
chromatography (60% w/w SiO2, EtOAc/ hexane, 1:4) to afford 1.26g, 66% of 50a as a clear 
light yellow oil.  1H NMR:  7.3-7.22 (m, 10H), 5.63-5.61 (M, 1H), 5.39 (s, 1H), 4.36-4.20 (m, 
2H), 4.18-4.10 (m, 2H), 4.04-3.98 (m, 2H), 2.55-2.45 (m, 1H) 2.27-2.07 (m, 1H) 1.95-1.86 (m, 
2H), 1.64-1.59 (m, 2H), 1.30-1.21 (m, 3H).   
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3-(2-Diarylmethoxy-ethylidene)- N-ethoxycarbonyl-8-azabicyclo[3.2.1]octane (50b) 
            In a clean, dry 10 mL round-bottom flask was added the alcohol (1.4 g, 6.2 mmol), bis-4-
fluorophenylmethylchloride or chlorodiphenylmethane (1.5 equivalents, 1.70 mL, 9 mmol) and a 
stir bar.  This was heated neat to 145 °C for 2 hours under N2.  The reaction was cooled to room 
temperature, dissolved in pure ethyl acetate and purified immediately by column 
chromatography (60% w/w SiO2, EtOAc/ hexane, 1:4) to afford 2.0 g, 75% of 50b as a clear 
light yellow oil.  1H NMR:  7.3-7.26 (m, 4H), 7.03-6.98 (m, 4H), 5.63-5.61 (M, 1H), 5.39 (s, 
1H), 4.36-4.20 (m, 2H), 4.18-4.10 (m, 2H), 4.04-3.98 (m, 2H), 2.55-2.45 (m, 1H) 2.27-2.07 (m, 
1H) 1.95-1.86 (m, 2H), 1.64-1.59 (m, 2H), 1.30-1.21 (m, 3H).   
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3-(2-Diarylmethoxy-ethylidene)-8-azabicyclo[3.2.1]octane (51) 
            In a clean 250 mL round-bottom flask was added ethylene glycol (88 mL), 26 equivalents 
KOH (4.42 g, 79 mmol), 5 equivalents NH2NH2• H2O (.75 mL, 15 mmol) and the corresponding 
protected tropane (1.26 g, 3 mmol).  The reaction was heated to reflux for 3 hours. The reaction 
was then cooled to room temperature and poured into a separatory funnel and extracted with 
diethyl ether (6  75 mL).  The combined ether layers were dried over Na2SO4, filtered and 
concentrated under reduced pressure.  The resulting oil was purified by column chromatography 
(SiO2, CHCl3/MeOH/NH4OH 90:9:1.) to afford the nortropane 51 as a light yellow oil.   
51a 615 mg, 60% 1H NMR:  7.36- 7.22 (m, 10H), 5.51-5.48 (M, 1H), 5.40 (s, 1H), 4.05-3.97 
(m, 2H), 3.57-3.54 (m, 2H), 2.43-2.40 (d, J = 13.6 Hz, 1H), 2.28-2.25 (d, J = 14.0 Hz, 1H) 2.09-
2.01 (t, J = 14.0 Hz, 2H) 1.84 (bs, 2H), 1.73-1.68 (m, 2H) 1.64-1.59 (m, 1H), 1.51-1.47 (m, 1H). 
13C NMR:  142.1(2), 138.0(4), 128.1(4), 126.8(2), 122.9, 82.3, 64.1, 55.1, 54.7, 43.8, 36.9, 29.1, 
28.8(2).  Anal. Calc. for C22H25NO•0.25 H2O: C, 81.75; H, 7.93; N, 4.33 Found: C, 81.57; H, 
7.86; N, 4.35.64 
51b 577 mg, 66% 1H NMR:  7.36- 7.22 (m, 4H), 7.02-6.97 (m, 4H) 5.51-5.48 (m, 1H), 5.40 (s, 
1H), 4.05-3.97 (m, 2H), 3.57-3.54 (m, 2H), 2.43-2.40 (d, J = 13.6 Hz, 1H), 2.28-2.25 (d, J = 14.0 
Hz, 1H) 2.09-2.01 (t, J = 14.0 Hz, 2H) 1.84 (bs, 2H), 1.73-1.68 (m, 2H) 1.64-1.59 (m, 1H), 1.51-
1.47 (m, 1H). 13C NMR:  158.14(2), 138.3, 138.1, 134.4(4), 128.5(2), 128.3(2), 123.1, 115.0, 
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81.2, 69.4, 64.1, 55.2, 54.8, 43.8, 36.9, 29.2.  Anal. Calc. for C22H23F2NO•0.50 H2O: C, 72.50; H, 
6.63; N, 3.84 Found: C, 72.55; H, 6.50; N, 3.84.64 
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General procedure for N-alkylation of secondary amines (28a-i) 
             In a clean, dry 25 mL round-bottom flask was added 600 mg K2CO3, the nortropane 51 
(2 mmol), DMF (15 mL) and the alkyl bromide (2 mmol) and a stir bar.  The reaction was heated 
to 80 °C (oil bath) overnight under N2.  The reaction was cooled to room temperature and added 
to a separatory funnel followed by addition of H2O (50 mL).  The mixture was extracted with 
diethyl ether (4 50 mL) and the combined organic layers were dried over Na2SO4, filtered and 
concentrated under reduced pressure.  The oil was purified by column chromatography and the 
pure free base was converted into the oxalate salt. 
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3-(2-Diphenylmethoxy-ethylidene)-8-alkyl-8-azabicyclo[3.2.1]octane (28Ha) 
The oil was purified by column chromatography  (SiO2, EtOAc) to give 28a as a thick 
yellow oil (642 mg, 78%). 1H NMR (400 MHz, CDCl3)  7.04-7.21 (m, 15H), 5.52-5.49 (t, J=8 
Hz, 1H), 5.39 (s, 1H), 4.05-3.96 (m, 2H), 3.61 (s, 2H), 3.23-3.20 (d, J=12 Hz, 2H), 2.62-2.59 (d, 
J=12 Hz, 1H), 2.24-2.09 (dd, J=14 Hz, 2H), 1.95-1.92 (m, 3H), 1.59-1.54 (t, J=8 Hz, 1H), 1.47-
1.42 (t, J=10 Hz, 1H).  Anal. Calc. for C29H31NO•C2H2O4:  C 74.58; H 6.66; N 2.81.  Found: C 
74.62; H 6.71; N 2.79. 
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(+)-3-(2-Diphenylmethoxy-ethylidene)-8-benzyl-8-azabicyclo[3.2.1]octane (+)-(28Ha) 
To a solution of the racemic 28a (350 mg, 0.85 mmol) in MeOH (10 mL), was added a 
solution of dibenzoyl-L-tartaric acid (310 mg, 0.87 mmol) in MeOH (10 mL).  This was allowed 
to stir at room temperature for 5 hours.  A white precipitate formed after approximately 30 
minutes.  The precipitate was collected by filtration through a Buchner funnel and washed with 
MeOH (5 mL).  The solid was added to a flask in addition to H2O (20 mL).  The chiral salt was 
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free-based with NH4OH when a pH=12 was reached.  The solution was extracted with CHCl3 (4 
 10 mL).  The combined organic layers were dried over Na2SO4, filtered and concentrated under 
reduced pressure to produce a clear oil.  The freebase was treated with a second equivalent of 
dibenzoyl-L-tartaric acid and the recrystallization process was repeated until a constant optical 
rotation was obtained.  The resolved 28a was obtained as a clear oil, 96 mg, []25D +17.0° (c 1.0, 
EtOH). 
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(-)-3-(2-Diphenylmethoxy-ethylidene)-8-benzyl-8-azabicyclo[3.2.1]octane (-)-(28Ha) 
To a solution of the racemic 28Ha (189 mg, 0.46 mmol) in MeOH (10 mL), was added a 
solution of dibenzoyl-D-tartaric acid (166 mg, 0.46 mmol) in MeOH (10 mL).  The mixture was 
allowed to stir at room temperature for 5 hours.  A white precipitate formed after approximately 
30 minutes.  The precipitate was collected by filtration through a Buchner funnel and washed 
with MeOH (5 mL).  The solid was added to a flask in addition to H2O (20 mL).  The chiral salt 
was free-based with NH4OH when a pH=12 was reached.  This was extracted with CHCl3 (4  10 
mL).  The combined organic layers were dried over Na2SO4, filtered and concentrated under 
reduced pressure to produce a clear oil.  The freebase was treated with a second equivalent of 
dibenzoyl-D-tartaric acid and the recrystallization process was repeated until a constant optical 
rotation was obtained.  The resolved 28a was obtained as a clear oil, 64 mg []25D -17.5° (c 1.25, 
EtOH). 
  
 
77 
N
O
 
3-(2-Diphenylmethoxy-ethylidene)-8-ethyl-8-azabicyclo[3.2.1]octane (28Hb) 
             The oil was purified by column chromatography  (SiO2, EtOAc) to give 28Hb as a thick 
oil (207 mg, 50%). 1H NMR (400 MHz, CDCl3)  7.35-7.22 (m, 10H), 5.53-5.50 (t, J=6.6 Hz, 
1H), 5.39 (s, 1H), 4.05-3.94 (m, 2H), 3.36-3.32 (d, J=16 Hz, 2H), 2.66-2.62 (d, J=16 Hz, 1H), 
2.57-2.52 (q, J=7 Hz, 2H), 2.28-2.25 (d, J=13.2 Hz, 1H), 2.13-2.10 (d, J=14 Hz, 1H) 1.96-1.93 
(d, J=14.4 Hz, 1H), 1.87 (s, 2H), 1.59-1.54 (t, J=9.2 Hz, 1H), 1.46-1.42 (t, J=8.8 Hz, 1H), 1.17-
1.13 (t, J=7.2 Hz, 3H). Anal. Calc. for C24H29NO•C2H2O4:  C 70.58; H 7.47; N 3.17.  Found: C 
70.56; H 7.39; N 3.10. 
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3-{2-Bis(4-fluorophenyl)methoxy-ethylidene}-8-ethyl-8-azabicyclo[3.2.1.]octane (28Fb) 
           The oil was purified by column chromatography  (SiO2, EtOAc) to give 28Fb as a thick 
yellow oil (140 mg, 66%). 1H NMR (400 MHz, CDCl3)  7.29-7.26 (m, 4H), 7.03-6.98 (m, 4H), 
5.49 (s, 1H), 5.33 (s, 1H), 4.01-3.91 (m, 2H), 3.31-3.28 (d, J=12 Hz, 2H), 2.58-2.47 (m, 3H), 
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2.21-2.17 (d, J=16 Hz, 1H), 2.09-2.05 (d, J=16 Hz, 1H), 1.13-1.09 (t, J=8 Hz, 3H).  Anal. Calc. 
for C24H27F2NO•C2H2O4:  C 60.17; H 5.98; N 2.70.  Found: C 60.10; H 5.88; N 2.45. 
 
N
O
 
3-(2-Diphenylmethoxy-ethylidene)-8-propyl-8-azabicyclo[3.2.1]octane (28Hc) 
The oil was purified by column chromatography (SiO2, EtOAc) to give 28Hc as a thick 
yellow oil (72 mg, 42%). 1H NMR (400 MHz CDCl3)  7.35-7.22 (m, 10H), 5.54 (s, 1H), 5.39 (s, 
1H), 4.05-3.94 (m, 2H), 3.38 (bs, 2H), 2.49 (bs, 2H), 2.16 (d, J=13.2 Hz, 2H), 1.98-1.91 (m, 3H), 
1.61 (bs, 5H), 0.95 (t, J=7.4 Hz, 3H). Anal. Calc. for C27H31NO•C2H2O4:  C 69.06; H 7.51; N 
2.98.  Found: C 69.67; H 7.30; N 3.01. 
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3-{2-Bis(4-fluorophenyl)methoxy-ethylidene}-8-propyl-8-azabicyclo[3.2.1.]octane (28Fc) 
            The oil was purified by column chromatography  (SiO2, EtOAc) to give 28Fc as a thick 
yellow oil (64 mg, 68%).  1H NMR (400 MHz, CDCl3)  7.29-7.26 (m, 4H), 7.03-6.98 (m, 4H), 
5.45 (bs, 1H), 5.35 (s, 1H), 3.98-3.93 (m, 2H), 3.26 (bs, 2H), 2.57-2.54 (d, J=12 Hz, 1H), 2.40-
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2.36 (t, J=8 Hz, 2H), 2.16-2.04 (m, 2H), 1.92-1.84 (m, 3H) 1.56-1.50 (m, 3H) 1.36 (s, 1H) 0.93-
0.89 (t, J=7.2 Hz, 3H). Anal. Calc. for   C25H29F2NO•C2H2O4:  C 62.97; H 6.41; N 2.72.  Found: 
C 62.91; H 5.89; N 2.72. 
 
N
O
 
3-(2-Diphenylmethoxy-ethylidene)-8-(3-prop-2-ynyl)-8-azabicyclo[3.2.1]octane (28Hd) 
            The oil was purified by column chromatography  (SiO2, EtOAc) to give 28Hd as a thick 
yellow oil (169 mg, 61%).   1H NMR (400 MHz, CDCl3)  7.35-7.23 (m, 10H), 5.51 (t, J-6.4 Hz, 
1H), 5.39 (s, 1H), 4.05-3.93 (m, 2H), 3.41-3.38 (d, J=12 Hz, 2H), 3.22 (s, 2H), 2.59-2.55 (d, 
J=16 Hz, 1H), 2.20-2.13 (m, 2H), 1.99-1.96 (d, J=12 Hz, 1H), 1.85 (bs, 2H) 1.59-1.56 (d, J=12 
Hz, 2H) 1.46-1.42 (t, J=4.4 Hz, 1H).  Anal. Calc. for   C25H27NO•C2H2O4:  C 68.98; H 6.60; N 
2.98.  Found: C 68.67; H 6.36; N 2.93. 
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3-{2-Bis(4-fluorophenyl)methoxy-ethylidene}-8-(3-prop-2-ynyl)-8-azabicyclo[3.2.1.]octane 
(28Fd) 
            The oil was purified by column chromatography  (SiO2, EtOAc) to give 28Fd as a thick 
yellow oil (130 mg, 63%).  1H NMR (400 MHz, CDCl3)  7.29-7.26 (m, 4H), 7.03-6.98 (m, 4H), 
5.50 (t, J=8 Hz, 1H), 5.34 (s, 1H), 4.01-3.90 (m, 2H), 3.41 (bs, 2H), 3.20 (s, 2H), 2.59-2.56 (d, 
J=14 Hz, 1H), 2.21-2.12 (m, 2H), 1.88-1.86 (m, 1H), 1.56 (s, 2H) 1.43-1.39 (m, 2H).  Anal. Calc. 
for   C25H25F2NO•C2H2O4:  C 64.60; H 5.78; N 2.79.  Found: C 63.80; H 5.50; N 2.59. 
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8-Allyl-3-(2-diphenylmethoxy-ethylidene)-8-azabicyclo[3.2.1]octane (28He) 
            The oil was purified by column chromatography  (SiO2, EtOAc) to give 28He as a thick 
yellow oil (132 mg, 67%). 1H NMR (400 MHz, CDCl3)  7.35-7.21 (m, 10H), 5.96 (bs, 1H), 5.52 
(bs, 1H), 5.39 (s, 1H), 5.21-5.14 (t, J=17.6 Hz, 2H) 4.05-3.93 (m, 2H) 3.32-3.29 (d, J=12 Hz, 
2H), 3.12-3.10 (d, J=5.6 Hz, 2H), 2.63 (bs, 1H), 2.24 (bs, 1H), 2.16-2.12 (d, J=14 Hz, 1H), 1.98-
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1.95 (d, J=12 Hz, 1H), 1.86 (bs, 2H), 1.60-1.43 (m, 2H).  Anal. Calc. for C25H29NO•C2H2O4:  C 
68.64; H 6.99; N 2.97.  Found: C 68.55; H 6.88; N 2.78. 
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8-Allyl-3-{2-bis(4-fluorophenyl)methoxy-ethylidene}-8-azabicyclo[3.2.1.]octane (28Fe) 
            The oil was purified by column chromatography  (SiO2, EtOAc) to give 28Fe as a thick 
yellow oil (158 mg, 66%). 1H NMR (400 MHz, CDCl3)  7.29-7.26 (m, 4H), 7.03-6.98 (m, 4H), 
5.94 (bs, 1H), 5.48 (bs, 1H), 5.34 (s, 1H), 5.20-5.15 (d, J=17.6 Hz, 2H), 4.01-3.90 (m, 2H), 3.28 
(bs, 2H), 3.08 (bs, 2H), 2.56 (bs, 1H), 2.12 (m, 2H), 1.97-1.86 (m, 2H), 1.55 (s, 3H). Anal. Calc. 
for   C25H27F2NO•C2H2O4:  C 64.35; H 6.16; N 2.78.  Found: C 64.32; H 6.02; N 2.70. 
 
N
O
 
3-(2-Diphenylmethoxy-ethylidene)-8-cyclopropylmethyl-8-azabicyclo[3.2.1]octane (28Hf) 
            The oil was purified by column chromatography  (SiO2, EtOAc) to give 28Hf as a thick 
yellow oil (227 mg, 45%). 1H NMR (400 MHz, CDCl3)  7.36-7.23 (m, 10H), 5.48 (t, J=6.8 Hz, 
1H), 5.39 (s, 1H), 4.05-3.94 (m, 2H), 3.43-3.39 (d, J=16 Hz, 2H), 2.57-2.54 (d, J=12 Hz, 1H), 
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2.34-2.33 (d, J=4 Hz, 2H), 2.20-2.07 (m, 3H), 1.93-1.80 (m, 3H), 1.60-1.37 (m, 1H), 0.94 (m, 
1H), 0.52 (m, 2H), 0.12 (m, 2H).  Anal. Calc. for   C26H31NO•C2H2O4:  C 69.12; H 6.99; N 2.88.  
Found: C 69.00; H 6.97; N 2.83. 
 
N
O
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F  
3-{2-Bis(4-fluorophenyl)methoxy-ethylidene}-8-cyclopropylmethyl-8-
azabicyclo[3.2.1.]octane (28Ff) 
            The oil was purified by column chromatography  (SiO2, EtOAc) to give 28Ff as a thick 
yellow oil (140 mg, 65%). 1H NMR (400 MHz, CDCl3)  7.29-7.26 (m, 4H), 7.03-6.98 (m, 4H), 
5.46 (bs, 1H), 5.35 (s, 1H), 4.01-3.90 (m, 2H), 3.42 (bs, 2H), 2.56 (bs, 1H), 2.17 (bs, 1H), 2.10-
2.06 (d, J=14.8 Hz, 1H), 1.95-1.91 (d, J=14.4 Hz, 1H), 1.83 (bs, 2H), 1.58 (bs, 2H), 0.52-0.50 (d, 
J=7.2 Hz, 2H), 0.11-0.10 (d, J=4 Hz, 2H).  Anal. Calc. for   C26H29F2NO•C2H2O4:  C 65.00; H 
6.40; N 2.70.  Found: C 63.42; H 6.07; N 2.50. 
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3-(2-Diphenylmethoxy-ethylidene)-8-(4-fluorobenzyl)-8-azabicyclo[3.2.1]octane (28Hg) 
The oil was purified by column chromatography  (SiO2, EtOAc) to give 28Hg as a thick 
yellow oil (77 mg, 67%). 1H NMR (400 MHz, CDCl3)  7.38-7.21 (m, 12H) 7.04-6.97 (m, 2H) 
5.53-5.50 (t, J=6.4 Hz, 1H) 5.39 (s, 1H) 4.04-3.94 (m, 2H) 3.58 (s, 2H) 3.22 (s, 2H) 2.63-2.60 (d, 
J=13.2 Hz, 1H) 2.25-2.22 (d, J=14 Hz, 1H) 2.14-2.10 (d, J=14 Hz, 1H) 1.92 (bs, 3H) 1.60-1.53 
(m, 2H). Anal. Calc. for   C29H30FNO•C2H2O4: C 71.94; H 6.23; N 3.67.  Found: C 66.30; H 5.98; 
N 2.44. 
 
N
O
F
F
F
 
8-(4-Fluorobenzyl)-3-{2-bis(4-fluorophenyl)methoxy-ethylidene}-8-azabicyclo[3.2.1.]octane 
(28Fg) 
            The oil was purified by column chromatography (SiO2, EtOAc) to give 28Fg as a thick 
yellow oil (73 mg, 87%).  1H NMR (400 MHz, CDCl3)  7.37-7.25 (m, 6H) 7.06-6.98 (m, 6H) 
5.50-5.47 (t, J=6.8 Hz, 1H) 5.35 (s, 1H) 4.01-3.92 (m, 2H) 3.56 (s, 2H) 3.21-3.20 (d, J=4 Hz, 
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2H) 2.60-2.57 (d, J=13.6 Hz, 1H) 2.19-1.90 (m, 5H) 1.56 (t, J=10 Hz, 1H) 1.42 (t, J=10 Hz, 1H).  
Anal. Calc. for   C29H28F3NO•C2H2O4:  C 67.26; H 5.46; N 2.53.  Found: C 66.44; H 5.45; N 
2.56. 
 
N
O
Cl
 
3-(2-Diphenylmethoxy-ethylidene)-8-(4-chlorobenzyl)-8-azabicyclo[3.2.1]octane (28Hh) 
            The oil was purified by column chromatography  (SiO2, EtOAc) to give 28Hh as a thick 
yellow oil (95 mg, 93%). 1H NMR (400 MHz, CDCl3)  7.39-7.21 (m, 14H) 5.51 (bs, 1H) 5.38 
(s, 1H) 4.01-3.97 (m, 2H) 3.59-3.55 (d, J=16 Hz, 2H) 3.18-3.16 (d, J=6.8 Hz, 2H) 2.58-2.55 (d, 
J=12 Hz, 1H) 2.17-2.09 (m, 2H) 1.89 (bs, 3H) 1.58-1.44 (m, 2H). Anal. Calc. for   
C32H30ClNO•C2H2O4: C 69.72; H 6.04; N 2.62.  Found: C 66.30; H 5.98; N 2.44. 
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8-(4-Chlorobenzyl)-3-{2-bis(4-fluorophenyl)methoxy-ethylidene}-8-azabicyclo[3.2.1.]octane 
(28Fh) 
            The oil was purified by column chromatography (SiO2, EtOAc) to give 28Fh as a thick 
yellow oil (56 mg, 74%). 1H NMR (400 MHz, CDCl3)  7.35-7.23 (m, 8H) 7.04-6.97 (m, 4H) 
5.48 (t, J=6.8 Hz, 1H) 5.35 (s, 1H) 4.01-3.91 (m, 2H) 3.56 (s, 2H) 3.19 (bs, 2H) 2.60-2.56 (d, 
J=14.4 Hz, 1H) 2.22-2.19 (d, J=14 Hz, 1H) 2.11-2.08 (d, J=14 Hz, 1H) 1.96-1.86 (m, 3H) 1.56 (t, 
J=9 Hz, 1H) 1.42 (t, J=8.8 Hz, 1H). Anal. Calc. for C29H28F2ClNO•C2H2O4:  C 65.32; H 5.30; N 
2.46.  Found: C 63.74; H 5.26; N 2.63. 
 
N
O
H3C
 
3-(2-Diphenylmethoxy-ethylidene)-8-(4-methylbenzyl)-8-aza-bicyclo[3.2.1]octane (28Hi) 
The oil was purified by column chromatography  (SiO2, EtOAc) to give 28Hi as a thick 
yellow oil (74 mg, 60%). 1H NMR (400 MHz, CDCl3)  7.39-7.11 (m, 14H) 5.51-5.48 (t, J=6.4 
Hz, 1H) 5.39 (s, 1H) 4.04-3.97 (m, 2H) 3.56 (s, 2H) 3.22-3.19 (d, J=17.6 Hz, 2H) 2.61-2.57 (d, 
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J=13.6 Hz, 1H) 2.33 (s, 3H) 2.23-2.19 (d, J=14 Hz, 1H) 2.11-2.08 (d, J=14.4 Hz, 1H) 1.93 (bs, 
3H) 1.57-1.43 (m, 2H). Anal. Calc. for   C30H33NO•C2H2O4: C 74.83; H 6.87; N 2.73.  Found: C 
66.30; H 5.98; N 2.44. 
 
N
O
F
F
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3-{2-Bis(4-fluorophenyl)methoxy-ethylidene}-8-(4-methylbenzyl)-8-azabicyclo[3.2.1.]octane 
(28Fi) 
            The oil was purified by column chromatography  (SiO2, EtOAc) to give 28Fi as a thick 
yellow oil (153 mg, 85%). 1H NMR (400 MHz, CDCl3)  7.21-7.16 (m, 4H) 7.06-7.04 (d, J=8 
Hz, 4H) 6.94-6.90 (m, 4H) 5.41-5.39 (t, J=8 Hz, 1H) 5.27 (s, 1H) 3.90-3.86 (m, 2H) 3.49 (s, 2H) 
3.16-3.13 (m, 2H) 2.54-2.50 (d, J=16 Hz, 1H) 2.26 (s, 3H) 2.16-2.12 (d, J=14 Hz, 1H) 2.02-1.99 
(d, J=14 Hz, 1H) 1.86-1.83 (m, 3H) 1.50-1.44 (t, J=8 Hz, 1H) 1.35-1.31 (t, J=8 Hz, 1H). Anal. 
Calc. for   C30H31F2NO•C2H2O4•H2O: C 67.71; H 6.22; N 2.47.  Found: C 66.30; H 5.98; N 2.44. 
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2-Bromopropenamine (61) 
            In a 1L 3-neck round bottom flask was added 2 equivalents of hexamethylenetetramine 
(126 g, 0.90 mol), CHCl3 (800 mL) and fitted with a Hershberg stirrer.  The mixture was brought 
to reflux with stirring while adding via an addition funnel 2, 3-dibromopropene, 80% (100 g, 
0.40 mol) over one hour.  The mixture was refluxed an additional 3 hours then cooled to room 
temperature overnight without stirring.  The mixture was cooled in an ice bath and the salt 
filtered via vacuum filtration.  The salt was allowed to air-dry overnight.   
            The salt was added to EtOH (2 L), 12N HCl (480 mL) and H2O (400 mL).  This was 
allowed to stir one hour then let stand at room temperature for 24 hours.  The salt was removed 
by vacuum filtration and the filtrate concentrated to approximately 600 mL.  The filtrate was 
filtered again and concentrated to dryness.  The solid residue was dissolved in H2O (300 mL) and 
the pH adjusted to pH = 13 with 6N NaOH (200 mL).  The aqueous mixture was extracted with 
diethyl ether (3  100 mL).  The organic layer was dried over Na2SO4, filtered and concentrated 
under reduced pressure.  The residue was distilled under reduced pressure to afford 61 as an off-
white solid (44g, 81%), which was immediately utilized in the next step. 1H NMR (400 MHz, 
CDCl3)  5.78 (s, 1H) 5.48 (s, 1H) 3.48 (s, 2H) 1.60 (bs, 2H).65 
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2, 3-Tribromopropylamine•HBr (48) 
            The amine from the previous step was dissolved in H2O (70 mL) and brought to 0° C on 
an ice bath.  HBr (48% solution, 40.5 mL, 0.36 mol) was added slowly with stirring followed by 
slow addition of Br2 (25 mL, 0.49 mol).  The mixture was allowed to stir at room temperature for 
24 hours.  The mixture was then concentrated under reduced pressure to afford 48 as an orange-
white solid (104g, 85%).  mp 196°-198° C [lit.60 196-198° C]. 1H NMR (400 MHz, D2O)  4.35 
(s, 2H) 3.82 (s, 2H). Anal. Calc. for   C3H6NBr3•HBr: C 9.56; H 1.87; N 3.72.  Found: C 9.66; H 
1.81; N 3.70.  NMR data is comparable to ref. 60. 
  
N
OMeMeO
 
1-Benzyl-3-dimethoxyazetidine (46) 
            In a 250 mL round bottom flask were added the amine (4.02g, .011 mol), benzaldehyde 
(1.2 mL, .011 mol), BF3•Et2O (3 drops), triethylamine (3 mL, .022 mol), H2O (10 mL) and 
benzene (100 mL).  This was fitted with a Dean-Stark trap and refluxed overnight.  The mixture 
was cooled to room temperature and diethyl ether (100 mL) was added.  The triethylammonium 
salts were filtered and the solvent evaporated under reduced pressure.  The residue was dissolved 
in dry MeOH (50 mL) and flushed with N2.  The mixture was cooled to 0° C on an ice bath and 
NaBH4 (1.01g, .022 mol) was added portionwise over 1 hour.  The mixture was allowed to warm 
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to room temperature and then heated to reflux overnight.  The mixture was concentrated under 
reduced pressure then dissolved in H2O (50 mL) and extracted with CH2Cl2 (4  30 mL).  The 
combined organic layers were dried over Na2SO4, filtered and concentrated under reduced 
pressure.  The oil was purified by column chromatography  (SiO2, EtOAc/ hexanes 1:4) to give 
46 as a thick yellow oil (957 mg, 43%). 1H NMR (400 MHz, CDCl3)  7.32-7.31 (m, 5H) 3.73 (s, 
2H) 3.30 (s, 4H) 3.20 (s, 6H). NMR data is comparable to ref. 60. 
 
N
O
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1-Benzyl-3-methoxycarbethylidenylazetidine (62) 
            In a 50 mL round bottom flask were added the protected azetidine 46 (.741g, 3.58 mmol) 
and 10 eq. 18 M H2SO4 (2 mL).  The mixture was allowed to stir at room temperature for 3hours 
then cooled to 0° C on an ice bath.  The reaction was quenched with sat. NaOH (12 mL) and the 
residue dissolved with H2O (30 mL) and CH2Cl2 (30 mL).  The mixture was poured into a 
separatory funnel and the layers separated.  The aqueous layer was extracted with CH2Cl2 (4  20 
mL) and the combined organic layers were dried over Na2SO4, filtered and concentrated under 
reduce pressure.  The N-benzylazetidinone 37 was immediately carried on to the next step. 1H 
NMR (400 MHz, CDCl3)  7.35-7.34 (m, 5H) 4.08 (s, 4H) 3.88 (s, 2H).54 
            In a 100 mL round bottom flask were added LiCl (75 mg, 2.0 mmol), acetonitrile (25 
mL) and a stir bar.  Trimethylphosphonoacetate (0.22 mL, 2.0 mmol) was then added with 
stirring.  DBU (0.20 mL, 1.3 mmol) was added followed by the azetidinone 37.  The mixture was 
allowed to stir at room temperature overnight.  The mixture was concentrated under reduced 
pressure with minimal heat.  The residue was partitioned over in H2O (20 mL) and CH2Cl2 (30 
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mL) and added to a separatory funnel.  The layers were separated and the aqueous extracted with 
CH2Cl2 (4  20 mL).  The combined organic layers were dried over Na2SO4, filtered and 
concentrated under reduced pressure.  The oil was purified by column chromatography  (SiO2, 
EtOAc/ hexanes 1:3) to give 62 as a yellow oil (158 mg, 55% over two steps). 1H NMR (400 
MHz, CDCl3/TMS)  7.33-7.26 (m, 5H) 5.68 (bs, 1H) 4.26-4.25 (d, J = 2.8 Hz, 2H) 4.01-4.00 (d, 
J = 2.4 Hz, 2H) 3.78 (s, 2H) 3.68 (s, 3H).  13C NMR (400 MHz, CDCl3/ TMS)  166.1, 157.9, 
138.3, 128.6(4), 127.4, 111.9, 64.1, 63.2, 62.2, 51.1.  Anal. Calc. for   C13H15NO2•C2H2O4: C 
58.63; H 5.58; N 4.56.  Found: C 57.76; H 5.57; N 4.51.  M.p 147-150° C. 
 
N
O
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1-Benzyl-3-methoxycarbethylazetidine (63) 
            In a 100 ml round bottom flask were added the azetidine 62 (610 mg, 2.81 mmol), 10% 
Pd/C (65 mg) and dry THF (55 mL).  The flask was evacuate of all gases and sealed under H2 
gas (1 atm).  The mixture was allowed to stir at room temperature overnight.  The mixture was 
then filtered through a pad of Celite, washed with EtOAc (50 mL) and concentrated under 
reduced pressure to afford 63 as a yellow oil (611 mg, quantitative) without any further 
purification. ). 1H NMR (400 MHz, CDCl3/TMS)  7.17-7.07 (m, 5H), 3.46 (bs, 5H), 3.36-3.32 
(t, J = 7.2 Hz, 2H), 2.80-2.77 (t, J = 6.8 Hz, 2H), 2.69-2.66 (m, 1H), 2.45-2.43 (d, J = 7.6 Hz, 
2H). 13C NMR (400 MHz, CDCl3/ TMS)  172.6, 137.8, 128.7(2), 128.5(2), 127.3, 63.3, 59.8, 
51.5(2), 38.3, 27.2. Anal. Calc. for   C13H17NO2•C2H2O4: C 58.25; H 6.19; N 4.53.  Found: C 
57.96; H 6.21; N 4.56. M.p 156-157° C. 
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General Procedure for 1-Benzyl-3-diphenylmethoxyethylidenylazetidine (29a, b and 30a, b) 
            To a 100 mL round bottom flask was added LiAlH4 (30 mg, 0.8 mmol) and dry THF (10 
mL) then sealed under N2. The reaction was cooled to 0° C on an ice bath and the azetidine ester 
62 (123 mg, 0.6 mmol) in THF (3 mL) was added slowly via syringe.  The reaction was stirred at 
0° C for 2 hours and quenched with a 10% solution of KOH (0.5 mL).  The mixture was allowed 
to come to room temperature with stirring for 1 hour and then poured into a separatory funnel.  
The white solid in the flask was washed with CH2Cl2 (3  10 mL) and the washings added to the 
separatory funnel.  The organic layer was washed with phosphate buffer (30 mL) and the layers 
separated.  The aqueous layer was then extracted with CH2Cl2 (4  25 mL).  The combined 
organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure with 
minimal heat.  The crude alcohol was immediately added to a 100 mL round bottom flask and 
dissolved in benzene (70 mL).  PTSA (750 mg, 4.0 mmol) and the corresponding benzhydrol 
(1.85 g, 10 mmol) were added to the flask and fitted with a Dean-Stark trap.  The reaction was 
heated to reflux overnight. 
            The mixture was concentrated under reduced pressure and the residue was dissolved in 
CH2Cl2 (20 mL).  The organic phase was washed with saturated NaHCO4 (40 mL).  The layers 
were separated and the aqueous phase was extracted with CH2Cl2 (4  25 mL).  The organics 
were combined and dried over Na2SO4, filtered and concentrated under reduced pressure.   
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1-Benzyl-3-diphenylmethoxyethylidenylazetidine (29a) 
            The oil was purified by column chromatography (SiO2, EtOAc) to give 29a as a yellow 
oil (180 mg, 16% over two steps). 1H NMR (400 MHz, CDCl3/TMS)  7.35-7.21 (m, 15H) 5.45-
5.41 (m, 1H) 5.39 (s, 1H) 3.89-3.88 (d, J = 6.4 Hz, 4H) 3.82 (s, 2H) 3.71 (s, 2H).  13C NMR (400 
Mhz, CDCl3/ TMS)  142.4(2), 138.6, 136.8, 128.7(12), 127.7(2), 127.3, 117.3, 87.8, 65.7, 63.8, 
62.4, 61.5.  Anal. Calc. for   C25H25NO•C2H2O4: C 72.79; H 6.11; N 3.14.  Found: C 72.57; H 
6.08; N 3.29. M.p 146.5-147° C. 
 
N
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1-Benzyl-3-(bis-4-fluorophenyl)methoxyethylidenylazetidine (29b) 
            The oil was purified by column chromatography (SiO2, EtOAc) to give 29b as a yellow 
oil (80 mg, 16% over two steps). 1H NMR (400 MHz, CDCl3/TMS)  7.36-7.26 (m, 10H), 7.04-
7.00 (t, J = 8.4Hz, 4H), 5.45- 5.42 (m, 1H), 5.38 (s, 1H), 3.90-3.87 (t, J = 2.8Hz, 4H), 3.82 (s, 
2H), 3.73 (s, 2H).  13C NMR (400 MHz, CDCl3/ TMS)  163.7, 161.2, 138.6, 138.1, 138.0, 
137.3, 128.9(4), 128.8(2), 128.7(4), 127.4, 116.9(2), 115.7, 115.5, 81.3, 65.7, 63.8, 62.4, 61.4.  
Anal. Calc. for   C25H25NO•C2H2O4: C 67.35; H 5.23; N 2.91. 
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1-Benzyl-3-diphenylmethoxyethylazetidine (30a) 
            The oil was purified by column chromatography (SiO2, EtOAc) to give 30a as a yellow 
oil (142 mg, 30% over two steps). 1H NMR (400 MHz, CDCl3/TMS)  7.38-7.25 (m, 15H), 5.33 
(s, 1H), 3.62 (s, 2H), 3.55-3.51 (t, J = 6.8Hz, 2H), 3.46-3.43 (t, J = 8.0Hz, 2H), 2.89-2.85 (t, J = 
6.8Hz, 2H), 2.75-2.71 (m, 1H), 1.94-1.90 (q, J = 6.8, 6.4Hz, 2H).  13C NMR (400 Mhz, CDCl3/ 
TMS)  142.7(2), 138.6, 128.8(4), 128.7(2), 128.6(4), 127.7(2), 127.2, 127.1(2), 84.0, 67.6, 64.3, 
61.1(2), 34.9, 29.1.  Anal. Calc. for C25H27NO•C2H2O4•0.25H2O: C 71.74; H 6.58; N 3.10.  
Found: C 71.72; H 6.53; N 3.11. M.p 146.5-147.5° C. 
 
N
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1-Benzyl-3-diphenylmethoxyethylazetidine (30b) 
The oil was purified by column chromatography (SiO2, EtOAc) to give 30b as a yellow 
oil (223 mg, 49% over two steps). 1H NMR (400 MHz, CDCl3/TMS)  7.35-7.24 (m, 8H), 7.04-
7.00 (m, 4H), 5.26 (s, 1H), 3.69 (s, 2H), 3.51-3.47 (t, j = 6.4 Hz, 2H), 3.40-3.37 (t, 6.0Hz, 2H), 
2.85-2.82 (t, J = 7.6 Hz, 2H), 2.70-2.66 (m, 1H), 1.91-1.86 (q, J = 6.0, 7.2 Hz, 2H).  13C NMR 
(400 Mhz, CDCl3/ TMS)  163.6, 161.2, 138.3(3), 128.7(8), 127.2, 115.6(2), 115.4(2), 82.6, 
67.6, 64.2, 60.9(2), 34.7, 29.1.  Anal. Calc. for C25H27NO•C2H2O4: C 67.07; H 5.63; N 2.90.  
Found: C 66.93; H 5.55; N 2.92. M.p 162.5-163° C 
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Dopamine Transporter Binding Assay. Binding of [3H]WIN 35,428 were done as described 
previously.60,61 Male Sprague-Dawley rats (200-250 g, Taconic, Germantown, NY) were 
decapitated and their brains removed to an ice-cooled dish for dissection of the caudate putamen.  
The tissue was homogenized in 30 volumes ice-cold modified Krebs-HEPES buffer (15 mM 
HEPES, 127 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 2.5 mM CaCl2, 1.3 mM NaH2PO4, 10 
mM D-glucose, pH adjusted to 7.4) using a Brinkman polytron and centrifuged at 20,000 x g for 
10 min at 4°C.  The resulting pellet was then washed two more times by resuspension in ice-cold 
buffer and centrifugation at 20,000 x g for 10 min at 4°C.  Fresh homogenates were used in all 
experiments.  Binding assays were conducted in modified Krebs-HEPES buffer on ice.  The total 
volume in each tube was 0.5 mL and the final concentration of membrane after all additions was 
0.5% (w/v) corresponding to 200-300 mg of protein/sample. [3H]WIN 35,428 (2-
carbomethoxy-3(4-fluorophenyl)tropane 1,5-naphthalene disulfonate; specific activity 82.4 
Ci/mmol, from New England Nuclear, Boston, MA) was added and the incubation was continued 
for 1 hr on ice. The incubation was terminated by the addition of 3 mL of ice-cold buffer and 
rapid filtration through Whatman GF/B glass fiber filter paper (presoaked in 0.1% BSA in water 
to reduce non-specific binding) using a Brandel Cell Harvester (Gaithersburg, MD).  The filters 
were washed with three additional 3 mL washes and transferred to scintillation vials.  Absolute 
ethanol (0.5 mL) and Beckman Ready Value Scintillation Cocktail (2.75 mL) was added to the 
vials, which was counted the next day at an efficiency of about 36%.  For determination of Ki 
values, triplicate samples of membrane suspension was preincubated for 5 min in the presence or 
absence of the compound being tested. Each compound was tested with concentrations ranging 
from 0.01 nM to 100 μM for competition against binding of [3H]WIN 35,428 (final 
concentration 1.5 nM), in three independent experiments.  Under these assay conditions, an 
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average experiment yielded approximately 6,000 dpm total binding per sample and 
approximately 250 dpm non-specific binding, defined as binding in the presence of 100 μM 
cocaine. Each assay was replicated three times, and Ki values were determined using PRISM. 
Serotonin transporter Binding Assay.  Brains from male Sprague-Dawley rats weighing 200-
225 g were removed, the midbrain was dissected and rapidly frozen. Membranes were prepared 
by homogenizing tissues in 20 volumes (w/v) of 50 mM Tris (120 mM NaCl, 5 mM KCl; pH 7.4 
at 25º C) using a Brinkman polytron (setting 6 for 20 sec) and centrifuged (20,000 x g) for 10 
min at 4º C.  The resulting pellet was resuspended in buffer and recentrifuged (20,000 x g for 10 
min at 4º C).  The final pellet was resuspended in cold buffer to a concentration of 15 mg/ mL 
(original wet weight).  Assays were conducted in the above Tris buffer at 25º C (room 
temperature).  The total volume of each tube was 0.5 mL and contained 1.4 nM [3H]citalopram 
(specific activity 80 Ci/mmol; New England Nuclear, Boston MA) and 1.5 mg midbrain tissue 
(original wet weight).  [3H]Citalopram was added and the incubation continued for 60 min at 
room temperature.  Incubations were terminated by rapid filtration through Whatman GF/B 
filters (presoaked in 0.3% polyethylenimine in water to reduce non-specific binding) using a 
Brandel R48 filtering manifold (Brandel Instruments Gaithersburg, MD).  The filters were 
washed twice with 5 mL cold buffer and transferred to scintillation vials.  Beckman Ready Safe 
(3.0 mL) was added and the vials were counted the next day using a Beckman 6000 liquid 
scintillation counter (Beckman Coulter Instruments, Fullerton, CA) at an efficiency of 36%.  
Nonspecific binding is determined using 10 μM fluoxetine (RBI, Natick, MA).  Each compound 
was tested at concentrations from 0.01 nM to 100 μM for competition against binding of 
[3H]citalopram, in three independent experiments, each performed in triplicate. Each assay was 
replicated three times, and Ki values will be determined using PRISM. 
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Norepinephrine Transporter Binding Assay.  Brains from male Sprague-Dawley rats 
weighing 200-225 g were removed, the frontal cortex was rapidly dissected and frozen.  
Membranes were prepared by homogenizing tissues in 20 volumes (w/v) of 50 mM Tris (120 
mM NaCl, 5 mM KCl; pH 7.4 at 25° C), using a Brinkman polytron (setting 6 for 20 sec) and 
centrifuged (50,000 x g) for 10 min at 4°C.  The resulting pellet was resuspended in buffer, 
recentrifuged (50,000 x g) for 10 min at 4°C and resuspended in buffer to a concentration of 80 
mg/mL.  Assays were conducted in the above Tris buffer on ice.  The total volume of each tube 
was 0.5 mL and contained 0.5 nM [3H]nisoxetine (specific activity 80 Ci/mmol, New England 
Nuclear, Boston, MA) and 8 mg frontal cortex tissue (original wet weight).  Triplicate samples of 
the membrane suspension were preincubated for 5 min in the presence or absence of the test 
compound.  [3H]Nisoxetine was added and the incubation continued for 1 hr on ice.  Incubations 
were terminated by rapid filtration through Whatman GF/B filters, presoaked in 0.05% 
polyethylenimine, using a Brandel R48 filtering manifold (Brandel Instruments Gaithersburg, 
MD).  The filters were washed twice with 5 mL cold buffer and transferred to scintillation vials.  
Beckman Ready Safe (3.0 mL) was added to the vials, which were counted using a Beckman 
6000 liquid scintillation counter (Beckman Coulter Instruments, Fullerton, CA) at an efficiency 
of 36%.  Nonspecific binding is defined as binding in the presence of 1 μM desipramine.  Each 
compound was tested at concentrations from 0.01 nM to 100 μM for competition against binding 
of [3H]nisoxetine, in three independent experiments, each performed in triplicate. Each assay was 
replicated three times, and Ki values were determined using PRISM. 
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